On this page
Quick Reference
Overview and Recommendations
Background
- •Understand the Fourth Universal Definition of Myocardial Infarction, which classifies AMI into five types based on pathophysiology. Type 1 is spontaneous MI due to plaque rupture or erosion; Type 2 results from supply-demand imbalance (e.g., anemia, tachycardia); Type 3 is sudden cardiac death; Type 4 is related to (PCI); and Type 5 is related to coronary artery bypass grafting (CABG).
- •Distinguish between and based on the initial electrocardiogram (ECG). STEMI requires immediate reperfusion due to transmural ischemia, while NSTEMI involves subendocardial ischemia and is managed with urgent or early invasive strategies depending on risk stratification.
- •Recognize the significance of (CS), the most lethal complication of AMI. It is characterized by systemic hypoperfusion due to cardiac pump failure and is staged from A (at risk) to E (extremis) using the SCAI classification system.
- •Identify non-atherosclerotic causes of MI, particularly in younger patients and women. (SCAD) is the leading cause of pregnancy-associated MI, while (Myocardial Infarction with Non-Obstructed Coronary Arteries) occurs in 5-10% of cases and requires specialized imaging like Cardiac MRI for diagnosis.
- •Appreciate the time-dependent nature of myocardial necrosis. The "progressive phase" of active necrosis begins at symptom onset, making the "door-to-balloon" time (target < 90 minutes) the most critical metric for improving survival in obstructive cases.
Evaluation
- •Suspect AMI in any patient presenting with acute chest pain, pressure, or discomfort, particularly if it radiates to the left arm, neck, or jaw. Be vigilant for atypical presentations in women, the elderly, and patients with diabetes, who may present with isolated dyspnea, nausea, or epigastric pain.
- •Obtain a 12-lead ECG within 10 minutes of first medical contact. Look for persistent ST-segment elevation in two contiguous leads (≥1 mm in most leads, or age/sex-specific thresholds in V2-V3) to diagnose STEMI.
- •Identify "Occlusion Myocardial Infarction" (OMI) patterns that may not meet formal STEMI criteria but indicate acute occlusion. These include de Winter T-waves (upsloping ST-depression with tall, symmetric T-waves), hyperacute T-waves, and Wellens' syndrome (biphasic or deeply inverted T-waves in V2-V3).
- •Order high-sensitivity cardiac troponin (hs-cTn) immediately at presentation (H0). Utilize the H0/H1 or H0/H2 rapid rule-out/rule-in algorithms; a very low H0 value in a patient symptomatic for >3 hours can often rule out AMI, while a significant absolute delta (change) at 1 or 2 hours suggests acute injury.
- •Perform a targeted physical examination to assess for hemodynamic stability and complications. Use the Killip classification: Class I (no heart failure), Class II (rales, S3 gallop), Class III (pulmonary edema), and Class IV ( with hypotension and hypoperfusion).
- •Rule out life-threatening mimics using the "Triple Rule Out" approach if the diagnosis is ambiguous. Consider (tearing pain, BP discrepancy), (pleuritic pain, tachycardia), and tension pneumothorax.
- •Calculate the GRACE or TIMI risk score to guide the urgency of intervention in NSTEMI. High-risk features (GRACE >140, dynamic ST changes) warrant an early invasive strategy within 24 hours.
- •Utilize point-of-care to identify regional wall motion abnormalities, which support the diagnosis of AMI and help exclude mechanical complications like papillary muscle rupture or ventricular septal defects.
- •Screen for metabolic mimics such as severe , which can produce "pseudo-infarction" ST-elevation patterns on ECG, especially in patients with known renal failure.
- •Consider Cardiac Magnetic Resonance (CMR) imaging within 7-14 days for patients with suspected . CMR is the gold standard for differentiating MI from or by identifying specific patterns of late gadolinium enhancement (LGE).
Management
- •Administer Aspirin 324 mg (chewed) immediately to all patients with suspected ACS unless a true allergy exists. This provides rapid platelet inhibition and is a cornerstone of early therapy.
- •Initiate a second antiplatelet agent (P2Y12 inhibitor) as soon as possible. For STEMI or high-risk NSTEMI, preferred agents include Ticagrelor 180 mg loading dose followed by 90 mg BID, or Prasugrel 60 mg loading dose (only if coronary anatomy is known and no history of stroke/TIA).
- •Provide anticoagulation with Unfractionated Heparin (UFH) 60 U/kg bolus (max 4000 U) followed by 12 U/kg/hr infusion, or Enoxaparin 1 mg/kg SC BID. UFH is preferred if the patient is proceeding immediately to the cath lab.
- •Activate the cardiac catheterization laboratory immediately for any patient with STEMI. The goal is primary PCI with a door-to-balloon time of < 90 minutes at PCI-capable centers or < 120 minutes if transfer is required.
- •Administer Fibrinolytic therapy (e.g., Tenecteplase weight-based bolus) only if primary PCI cannot be performed within 120 minutes of diagnosis and there are no contraindications (e.g., recent intracranial hemorrhage, active bleeding).
- •Restrict supplemental oxygen to patients with SaO2 < 90% or PaO2 < 60 mmHg. Routine oxygen in normoxic patients may cause coronary vasoconstriction and increase infarct size.
- •Manage ischemic pain with Sublingual Nitroglycerin 0.4 mg every 5 minutes (up to 3 doses). Avoid nitrates in patients with right ventricular infarction (leads V3R/V4R elevation) or recent phosphodiesterase inhibitor use (e.g., sildenafil).
- •Stabilize by maintaining a Mean Arterial Pressure (MAP) ≥ 65 mmHg. Use Norepinephrine 0.05–1.0 µg/kg/min as the first-line vasopressor; add Dobutamine 2.5–20 µg/kg/min if hypoperfusion persists despite adequate MAP.
- •Consider early mechanical circulatory support (MCS) with a microaxial flow pump (e.g., Impella) in patients with refractory cardiogenic shock (SCAI Stage D/E) to provide left ventricular unloading.
- •Initiate high-intensity (e.g., Atorvastatin 80 mg daily) as soon as possible, regardless of baseline LDL levels, for their pleiotropic plaque-stabilizing effects.
- •Start an ACE inhibitor (e.g., Lisinopril 5 mg daily) within 24 hours in patients with LVEF < 40%, hypertension, or diabetes, provided they are hemodynamically stable without hypotension.
- •Administer oral Beta-blockers (e.g., Metoprolol succinate 25-50 mg daily) within the first 24 hours only in stable patients. Avoid in those with signs of heart failure, low output states, or risk of cardiogenic shock.
- •Prescribe Mineralocorticoid Receptor Antagonists (MRA) like Eplerenone 25 mg daily for patients already on ACEi and Beta-blockers who have an LVEF ≤ 40% and either symptomatic heart failure or diabetes.
- •Refer all AMI survivors to a formal cardiac rehabilitation program. Participation significantly reduces all-cause mortality and improves functional capacity post-discharge.
- •Discharge criteria include hemodynamic stability for 24-48 hours, successful revascularization, absence of high-grade arrhythmias, and a clear plan for dual antiplatelet therapy (DAPT) adherence, typically for 12 months.
Board Review — High Yield
- •Type 2 MI — Myocardial injury due to supply-demand mismatch (e.g., sepsis, anemia) rather than primary plaque rupture.
- •Killip Class IV — Represents cardiogenic shock; the highest mortality risk category in AMI.
- •de Winter T-waves — Upsloping ST-depression with tall, peaked T-waves in precordial leads; signifies acute LAD occlusion.
- •SCAD — Spontaneous Coronary Artery Dissection; the most common cause of MI in pregnant and postpartum women.
- •S1Q3T3 — Classic but non-specific ECG finding for pulmonary embolism, a major differential for AMI.
- •H0/H1 Protocol — Use of high-sensitivity troponin at 0 and 1 hour to rapidly rule out (low delta) or rule in (high delta) AMI.
- •Right Ventricular Infarct — Suspect with inferior MI + ST-elevation in V4R; treat with fluids, avoid nitrates/diuretics.
- •Dressler Syndrome — Post-MI pericarditis occurring weeks later; autoimmune-mediated, treated with NSAIDs/Colchicine.
Deep Dive — Evidence Details
Definition, Synonyms, and Classification
- ▸AMI is defined by myocardial necrosis with at least one hs-cTn value above the 99th percentile URL.
- ▸STAMI is a newly recognized overlap phenotype of Superimposed Takotsubo and Acute Myocardial Infarction.
- ▸STEMI and NSTEMI are the primary ECG-based classifications, with STEMI typically requiring more urgent revascularization.
- ▸Inflammatory markers like IL-6 and CRP are critical in determining the severity and long-term prognosis of AMI.
- ▸Non-chest pain (NCP) presentations of STEMI occur and are associated with different demographic profiles and potentially worse outcomes.
- ▸Advanced imaging and AI-based models are now used to quantify infarct size and microvascular obstruction (MVO) heterogeneity.
Definition and Core Pathophysiology
Acute Myocardial Infarction (AMI) is defined as myocardial necrosis resulting from acute ischemia [174]. The clinical diagnosis is established by the detection of a rise and/or fall of cardiac biomarkers, preferably high-sensitivity cardiac troponin (hs-cTn), with at least one value above the 99th percentile upper reference limit (URL), accompanied by clinical evidence of ischemia [172]. This evidence may include symptoms of ischemia, new ischemic electrocardiographic (ECG) changes, or imaging evidence of new loss of viable myocardium [172][182]. Recent evidence emphasizes that AMI is not merely a localized vascular event but a systemic inflammatory process; biomarkers such as Interleukin-6 (IL-6) drive ischemia-reperfusion injury, and their inhibition is currently being explored to reduce myocardial damage [174].
Synonyms and Emerging Phenotypes
While traditionally referred to as a "heart attack," AMI encompasses several distinct clinical phenotypes. A newly recognized entity is STAMI (Superimposed Takotsubo and Acute Myocardial Infarction), an overlap syndrome where AMI and Takotsubo syndrome (TTS) coexist [175]. In a pooled analysis, STAMI patients had a mean age of 67 years, were predominantly female (69%), and presented as STEMI in 57% of cases [175]. This challenges the traditional view of TTS as a diagnosis of exclusion requiring the absence of obstructive coronary disease [175].
Clinical Classification by ECG Presentation
AMI is primarily classified based on the initial electrocardiographic presentation, which dictates immediate management strategies:
- ST-Elevation Myocardial Infarction (STEMI): Characterized by persistent ST-segment elevation, typically indicating complete coronary occlusion [174][181]. STEMI requires rapid revascularization, often coordinated through interhospital transfer calls that can now be summarized using Large Language Models (LLMs) to improve data accessibility [181].
- Non-ST-Elevation Myocardial Infarction (NSTEMI): Characterized by myocardial necrosis without persistent ST-elevation [174]. NSTEMI often occurs in patients with complex comorbidities; for instance, severe obesity (BMI ≥35 kg/m²) combined with high inflammation (CRP >2 mg/L) significantly increases 10-year all-cause mortality in critically ill NSTEMI patients [179]C.
Diagnostic and Risk Stratification Models
Modern classification relies on rapid algorithms and scoring systems to triage patients:
- 0/2-Hour Algorithm: A point-of-care (POC) hs-cTnI algorithm allows for rapid rule-out or rule-in of MI within two hours in the Emergency Department [172].
- SCARE Score: A clinical tool used by emergency medical communication centers to discriminate AMI in patients calling with non-traumatic chest pain [173].
- ASCVD Risk Models: Traditional models like the Framingham Risk Score (FRS) and ACC/AHA ASCVD 2013 are used to predict risk, though their performance varies in specific populations such as South Asians [176].
- SYNTAX Score: Quantifies the complexity of coronary anatomy, which can be predicted non-invasively using the serum biomarker LRG1 combined with LDL-C [183].
Complications and Quality of Life
Classification also extends to the presence of complications and the psychological impact of the event. Pericardial effusion (PE) is a notable complication in young AMI patients (<45 years), and the NT-proBNP/albumin ratio has emerged as a sensitive predictor for this condition [180]. Furthermore, AMI significantly impairs health-related quality of life (HRQoL). Depressive symptoms, measured by the HAM-D scale, are common post-infarction and correlate with worse functional outcomes [177][188]. Younger and middle-aged women (<60 years) report a high psychological and psychosocial burden during long-term follow-up [190].
| Biomarker/Index | Clinical Utility | Key Thresholds/Findings |
|---|---|---|
| hs-cTnI (POC) | Rapid 0/2-hour triage | 99th percentile URL for diagnosis [172] |
| IL-6 | Inflammatory damage marker | Target for tocilizumab therapy [174] |
| NT-proBNP/ALB | Predicts pericardial effusion | Useful in patients <45 years [180] |
| HGI | Glycation index in NSTEMI | Higher HGI associated with better survival [186] |
| AMR & HbA1c | Microvascular resistance | Jointly predict MACCE in diabetic STEMI [178] |
| LRG1 | Coronary complexity | Predicts high SYNTAX score [183] |
Etiology and Triggering Factors
- ▸Low-attenuation plaque (LAP) burden is a stronger predictor of MI than coronary stenosis.
- ▸JAK2 V617F mutations are specifically associated with plaque erosion rather than rupture.
- ▸SCAD-related STEMI carries a higher inpatient mortality risk than atherosclerotic STEMI in contemporary US cohorts.
- ▸AI-guided quantitative CT (AI-QCT) can identify patients who derive the most benefit from lipid-lowering medications.
- ▸Obstructive sleep apnea and nocturnal hypoxemia shift the circadian rhythm of MI onset toward the nighttime.
Atherosclerotic Plaque Morphology and Composition
Acute myocardial infarction (AMI) is primarily driven by the progression and instability of coronary atherosclerotic plaques. Recent evidence from the SCOT-HEART trial indicates that quantitative plaque burden, particularly low-attenuation plaque (LAP), is a superior predictor of fatal or nonfatal MI compared to traditional stenosis assessment [34]. Radiomic phenotypes of these plaques further enhance risk stratification by characterizing complex morphology beyond simple volume [34]. The ISCHEMIA trial confirmed that total plaque volume and composition, quantified via AI-guided quantitative computed tomography (AI-QCT), are independent prognosticators of cardiovascular death or MI [35].
Specific high-risk features identified by optical coherence tomography (OCT) include thin-cap fibroatheroma (TCFA), a minimum luminal area <3.5 mm², a lipid arc >180°, and the presence of macrophages [58]D. The CLIMA study demonstrated that these features significantly impact long-term outcomes over a 5-year follow-up [58]D. Furthermore, the burden of atherosclerosis, as measured by the Gensini score, independently predicts cardiac events, including MI and target vessel revascularization [202]. Plaque calcification also plays a role; regional levels of matrix Gla protein (MGP) and specific MGP polymorphisms are associated with plaque calcification and adverse clinical outcomes in ST-segment elevation myocardial infarction (STEMI) patients [193].
Metabolic and Genetic Drivers
Diabetes mellitus significantly alters plaque characteristics, leading to higher coronary artery calcium (CAC) scores and increased quantitative plaque burdens (calcified, non-calcified, and low attenuation) compared to non-diabetic patients, thereby worsening long-term outcomes [33].
Genetic factors are increasingly recognized as etiologic drivers. Clonal hematopoiesis of indeterminate potential (CHIP), specifically mutations with a variant allele frequency (VAF) >0.5%, is associated with major adverse cardiovascular events (MACE) and specific culprit lesion phenotypes in STEMI [54]D. The JAK2 V617F variant is particularly potent, substantially elevating MI risk; it is specifically linked to plaque erosion rather than rupture, a process potentially mediated by neutrophil activation [198]. In East Asian populations, RNF213 variants have been identified as genetic risk factors for vasospastic angina and fatal MI [199].
Spontaneous Coronary Artery Dissection (SCAD)
SCAD is a critical non-atherosclerotic cause of AMI, particularly in younger patients and women [31][45]C. While often involving the right coronary artery or septal branches, left main (LM) SCAD represents a rare but life-threatening presentation, occurring in a cohort where 80% are women with a mean age of 40 ± 11 years [31]. Diagnosis often requires advanced imaging such as OCT or intravascular ultrasound (IVUS) to visualize the false lumen, as standard angiography may only show moderate stenosis [45]C[46]C.
Patients presenting with STEMI secondary to SCAD face higher inpatient mortality, prolonged hospitalizations, and increased costs compared to non-SCAD STEMI patients [197]. The presence of cardiogenic shock in SCAD patients further worsens prognosis; these patients are more likely to be male and have a higher incidence of multi-vessel involvement compared to SCAD patients without shock [201]. Despite its severity, traditional cardiac rehabilitation uptake remains a challenge for SCAD survivors due to perceived lack of relevance or specialized protocols [200].
Inflammatory and Circadian Triggers
Residual inflammation remains a key therapeutic target. The lectin-like oxidized LDL receptor-1 (LOX-1) promotes atherosclerosis by scavenging oxidized LDL; however, phase 2 trials of LOX-1 inhibitors (MEDI6570) did not significantly reduce noncalcified plaque volume in the most diseased segments despite the biological rationale [32].
External triggers and physiological rhythms also influence MI onset. Obstructive sleep apnea (OSA) and nocturnal hypoxemia are significantly associated with the circadian rhythm of MI, specifically increasing the likelihood of MI onset during the night [195]. Additionally, periprocedural myocardial infarction (PMI) in NSTE-ACS patients can be predicted by pre-existing plaque features quantified by CCTA, such as lipid core volume [196].
| Feature | Threshold/Definition | Prognostic Impact |
|---|---|---|
| Thin-Cap Fibroatheroma (TCFA) | Fibrous cap thickness <65 μm | High risk for rupture [58]D |
| Minimum Luminal Area (MLA) | <3.5 mm² | Increased MACE risk [58]D |
| Lipid Arc | >180° | Marker of vulnerability [58]D |
| Macrophages | Presence on OCT | Indicator of active inflammation [58]D |
Differential Diagnosis
- ▸Acute aortic syndrome (AAS) is frequently misdiagnosed as MI due to ischemic ECG changes.
- ▸Chronic myocardial injury is defined by a troponin variation of ≤ 20% over sequential measurements.
- ▸Echocardiographic IAR and ILAR indexes help distinguish Takotsubo syndrome from anterior STEMI.
- ▸Hyperkalemia can mimic STEMI on EKG and present with neurological deficits.
- ▸Type 1 MI generally shows higher hs-cTnI and CK-MB levels than Type 2 MI.
- ▸Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare mimic causing acute right heart failure.
The differential diagnosis of acute myocardial infarction (AMI) is broad, encompassing life-threatening cardiovascular, pulmonary, and metabolic conditions. Accurate differentiation is critical, as misdiagnosis—particularly of acute aortic syndrome (AAS)—is associated with ischemic ECG changes and an initial suspicion of MI in a significant portion of cases [203].
Acute Aortic Syndromes (AAS)
Acute aortic syndrome, including aortic dissection (AD), remains a primary 'great imitator' of AMI. Missed AAS diagnoses are frequently associated with ischemic ECG changes that lead clinicians toward an initial suspicion of MI [203]. Patients with AD often present with similar symptoms to NSTEMI, such as chest pain and shortness of breath, making rapid distinction essential [212]D. Machine learning models utilizing clinical characteristics and laboratory results are being developed to improve diagnostic accuracy between NSTEMI and AD [212]D. Furthermore, undertriage in the emergency department (ED) significantly delays care for AD compared to STEMI [75]D. In cases of acute aortic dissection, rapid hemodynamic modulation using sodium nitroprusside may be indicated for afterload reduction [205].
Takotsubo Syndrome (TTS) and Myocarditis
Takotsubo syndrome often presents with overlapping clinical and echocardiographic features to anterior STEMI with apical involvement [206]. Novel echocardiographic indices, specifically the inferior-apex ratio (IAR) and infero-lateral-apex ratio (ILAR), have been validated to aid in the bedside discrimination of TTS from anterior AMI [206]. Additionally, right ventricular (RV) strain has been identified as a key feature in machine learning models using cardiac magnetic resonance (CMR) to distinguish TTS from AMI and acute myocarditis [74]D. While TTS is often triggered by stress, it can lead to refractory cardiogenic shock requiring mechanical support such as ECMO [208].
Type 1 vs. Type 2 Myocardial Infarction and Injury
Distinguishing Type 1 MI (T1MI; atherothrombotic) from Type 2 MI (T2MI; supply-demand mismatch) is vital to avoid unnecessary invasive procedures [210].
- Biomarker Profiles: T1MI typically exhibits higher peaks of high-sensitivity Troponin I (hs-cTnI) and creatine kinase-MB compared to T2MI [210].
- Chronic Injury: Chronic myocardial injury is defined by elevated cardiac troponin (cTn) values that vary by ≤ 20% on sequential measurements [204].
- Novel Assays: The ternary cTnI-cTnT-TnC (ITC) complex and 'long-cTnT' forms are being investigated to better differentiate MI from other causes of troponin elevation, such as atrial fibrillation [68]D[70]D.
- Machine Learning: Algorithms like MI3, combined with NT-proBNP and galectin-3, are showing promise in accurately differentiating MI types in the ED [73]D.
Pulmonary and Oncologic Emergencies
Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare but fatal condition that can present as sudden cardiac death or acute right heart failure, mimicking the hemodynamic collapse of a massive MI [71]D. It is characterized by rapid development of pulmonary hypertension in patients with often unknown adenocarcinoma [71]D.
Electrolyte and Metabolic Mimics
Hyperkalemia is a critical mimic that can present with ST-segment elevations on EKG and lateralizing extremity weakness, potentially leading to a misdiagnosis of both STEMI and stroke [65]C.
Sex-Specific Considerations
Female patients often present with unique challenges in the assessment of chest pain due to sex-related differences in pathophysiology and symptom presentation [213]D. They are frequently underdiagnosed or undertreated, which contributes to poorer outcomes [213]D.
Emerging Diagnostic Tools
- Genomics and Molecular Markers: Peripheral leukocyte mRNA expression (e.g., for Stanford Type A dissection) and DNA damage response (DDR) genes like CDK7 are being explored to distinguish AMI subtypes [69]D[211].
- Exosomal MicroRNA: Plasma exosomal miRNAs (e.g., miR-3473, miR-504) are emerging as novel biomarkers for early AMI recognition [72]D.
- MINOCA: For patients with Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA), multiparametric integration of non-invasive variables via LASSO regression is used to identify this heterogeneous entity [209].
| Condition | Key Differentiating Feature | Reference |
|---|---|---|
| Acute Aortic Dissection | Often associated with ischemic ECG changes; requires CT or machine learning models for NSTEMI distinction | [203], [212]D |
| Takotsubo Syndrome | IAR/ILAR echocardiographic indexes; RV strain on CMR | [206], [74]D |
| Type 2 MI | Lower troponin peaks; supply-demand mismatch rather than plaque rupture | [210], [73]D |
| Hyperkalemia | ST elevation with concurrent paralysis or weakness | [65]C |
| Chronic Injury | Troponin stability (≤ 20% change) over short intervals | [204] |
Supportive Care and Complication Management
- ▸SCAI classification is the gold standard for staging cardiogenic shock severity and guiding multidisciplinary Heart Team activation.
- ▸Mineralocorticoid receptor antagonists (MRAs) should be initiated within 60 days post-AMI for patients with LVEF <50%.
- ▸Microaxial flow pumps (mAFP) improve survival in STEMI-CS but increase BARC 3-5 bleeding risk to 26.3%.
- ▸Low free triiodothyronine (FT3) and high glycemic variability are significant predictors of post-infarction arrhythmias.
- ▸The CS4P risk score provides superior prognostic accuracy for cardiogenic shock compared to traditional models.
- ▸Varenicline is being investigated as a novel therapy for frequent PVCs (≥1,000/24 h) post-MI.
- ▸Concomitant IABP may be used with V-A ECMO to prevent left ventricular distension and promote myocardial recovery.
Management of Cardiogenic Shock (CS)
Cardiogenic shock (CS) remains a critical complication of acute myocardial infarction (AMI), characterized by high mortality and significant management variability [216]. Current consensus emphasizes standardized staging using the SCAI classification to guide therapy [216]. Key components of management include early recognition, continuous lactate monitoring, and the central role of echocardiography for hemodynamic assessment [216]. The CS4P biomarker-based risk score, which utilizes four specific proteins, has demonstrated advanced predictive metrics for mortality in both STEMI and NSTEMI patients, outperforming contemporary risk scores [93].
In patients with STEMI-related CS (STEMI-CS), cardiac arrest is a frequent concomitant event, occurring as out-of-hospital cardiac arrest (OHCA) in 34.8% of cases and in-hospital cardiac arrest (IHCA) in 21.7% [218]. Furthermore, spontaneous coronary artery dissection (SCAD) can lead to CS; these patients are statistically less likely to be female (OR 0.64) or have a history of prior MI (OR 0.71) compared to non-CS SCAD patients, yet they face significantly higher mortality [201].
Mechanical Circulatory Support (MCS)
The use of mechanical circulatory support in AMI-CS is evolving, though randomized controlled trials (RCTs) have shown inconsistent results due to heterogeneity in patient selection and intervention timing [217]. The DanGer Shock trial demonstrated that microaxial flow pumps (mAFP), such as the Impella, improve outcomes in STEMI-CS but are associated with a significant increase in major bleeding [94]. Specifically, BARC type 3-5 bleeding occurred in 26.3% of mAFP patients compared to 15.3% in those receiving standard care [94]. Despite these risks, mAFP support provides comparable benefits in both ischemic (AMI-CS) and non-ischemic cardiogenic shock [12]D.
For patients requiring veno-arterial extracorporeal membrane oxygenation (V-A ECMO) during percutaneous coronary intervention (PCI), the addition of an intra-aortic balloon pump (IABP) may be considered to mitigate ECMO-related left ventricular (LV) overload [225]. While the initial choice between IABP and mAFP remains debated in real-world settings, early hemodynamic-guided intervention is increasingly recommended [217][224]C. In cases of Killip class IV AMI complicated by pulseless ventricular tachycardia (VT) or ventricular fibrillation (VF), mAFP use has been investigated for its impact on 30-day mortality [219].
Heart Failure and Ventricular Remodeling
Heart failure (HF) is the primary cause of death following AMI recovery [115]D. Early initiation of mineralocorticoid receptor antagonists (MRAs)—defined as initiation during index hospitalization or within 60 days—is safe and effective for patients with post-AMI cardiac dysfunction, specifically those with a left ventricular ejection fraction (LVEF) <50% [99].
At the molecular level, adverse cardiac remodeling and fibrosis are promoted by the E3 ubiquitin ligase TRIM21, which mediates the K48-linked ubiquitination of the ALDH2 rs671 mutant [115]D. Clinically, insulin resistance, as measured by the triglyceride-glucose (TyG) index, is a potent predictor of in-hospital acute heart failure (AHF) following emergency PCI [111]D.
Arrhythmia and Electrophysiological Monitoring
Arrhythmias are common post-AMI and require nuanced management. New-onset atrial fibrillation (AF) is categorized by timing: early (during index hospitalization) or late (after discharge), both of which carry distinct prognostic implications [223]. High glycemic variability (GV) during hospitalization is significantly associated with an increased risk of AF and in-hospital mortality [222].
For ventricular arrhythmias (VA), plasma free triiodothyronine (FT3) levels serve as a novel biomarker; lower FT3 levels are independently associated with a higher risk of VA during hospitalization [101]. In patients with frequent premature ventricular complexes (PVCs) (≥1,000/24 h) at ≥4 weeks post-MI, the partial nicotinic acetylcholine receptor (nAChR) agonist varenicline has been explored as a novel non-ion channel-targeting antiarrhythmic [214].
Continuous monitoring via implantable cardiac monitors (ICM) was studied in the BIO|GUARD-MI trial, but the study was terminated prematurely due to performance bias in the unblinded treatment group, which reported a higher incidence of non-cardiovascular adverse events [215].
Renal and Metabolic Complications
Acute kidney injury (AKI) is a major predictor of mortality in AMI-related CS [221]. A LASSO regression-based nomogram has been developed to predict the need for in-hospital renal replacement therapy (RRT), facilitating earlier intervention [221]. Additionally, the use of intravenous antiplatelet therapies, such as cangrelor or glycoprotein IIb/IIIa inhibitors, in the context of CS requires a careful balance between preventing major adverse cardiovascular events (MACE) and minimizing the risk of major bleeding [220].
| Intervention | Population | Key Outcome | Statistical Threshold |
|---|---|---|---|
| mAFP (Impella) | STEMI-CS | BARC 3-5 Bleeding | 26.3% vs 15.3% (Standard Care) |
| MRA Initiation | AMI + LVEF <50% | Safety/Efficacy | Initiation within 60 days |
| Varenicline | Post-MI | PVC Reduction | Baseline PVCs ≥1,000/24 h |
| SCAI Staging | AMI-CS | Mortality Risk | Standardized Staging (A-E) |
Prognosis and Long-term Outcomes
- ▸Physiology-guided complete revascularization is superior to culprit-only strategies in patients ≥75 years, regardless of frailty status.
- ▸The stress hyperglycemia ratio (SHR) is a better predictor of in-hospital mortality than absolute glucose levels.
- ▸Residual global μQFR after PCI is a critical physiological predictor of long-term ACS outcomes.
- ▸Malnutrition (CONUT score 5-12) and frailty are independent predictors of poor prognosis in elderly STEMI patients.
- ▸Machine learning models using multiorgan body composition or routine lab data provide high-accuracy 1-year to 10-year mortality predictions.
Risk Stratification and Mortality Predictors
Prognosis following acute myocardial infarction (AMI) is increasingly determined by complex physiological and metabolic markers. A simple echocardiographic grading system reflecting the severity of myocardial injury has been validated for long-term mortality risk stratification; patients classified as Grade 4 (highest severity) exhibit significantly higher all-cause mortality over a median follow-up of 5.5 years [230]. Metabolic indices also provide critical prognostic value. The triglyceride-glucose (TyG) index is positively associated with all-cause mortality in patients with coronary artery disease (CAD), with AMI partially mediating this relationship [229]. Furthermore, plasma levels of soluble low-density lipoprotein receptor (sLDLR) have been identified as a novel biomarker, where the highest tertile of sLDLR is associated with increased risks of MI, heart failure, and cardiovascular mortality over a 12.8-year follow-up [231].
Glycemic Stress and Diabetes Outcomes
In patients with diabetes mellitus (DM) presenting with AMI, risk heterogeneity is high. A parsimonious admission-based model using routine variables has been developed to predict 180-day mortality, providing prognostic information beyond the standard GRACE score [233]. The stress hyperglycemia ratio (SHR), which reflects acute glycemic stress relative to chronic control, shows a significant dose-response relationship with in-hospital mortality [232]. Interestingly, while higher hemoglobin glycation index (HGI) is typically a risk marker, some studies in NSTEMI patients undergoing PCI suggest a more favorable survival profile for those with higher HGI over a 60-month follow-up [186].
Revascularization Strategies in Older and Frail Populations
For older patients (≥75 years) with MI and multivessel disease, physiology-guided complete revascularization is superior to culprit-only strategies [228]. This benefit is consistent across the spectrum of frailty, from non-frail to frail individuals as measured by the Clinical Frailty Scale (CFS) [121]. However, the benefit of an invasive strategy specifically in frail older patients with NSTEMI remains a subject of investigation, as secondary analyses of the SENIOR-RITA trial suggest that while frail patients are at higher risk for major adverse cardiovascular events (MACE), the relative advantage of invasive over conservative management requires careful stratification [226]. In patients undergoing transcatheter aortic valve replacement (TAVR) with concomitant CAD, performing PCI reduces MACE, though the efficacy in the most frail subsets remains uncertain [227].
Advanced Physiological Assessment and Body Composition
Post-procedural physiological assessment is a strong predictor of long-term outcomes. The residual global Murray law-based angiographic quantitative flow ratio (μQFR) provides significant prognostic value; lower residual μQFR values after PCI are associated with worse long-term clinical outcomes in ACS populations [120]. Beyond cardiac metrics, machine learning-derived multiorgan body composition from coronary CT angiography—specifically the volume and attenuation of segmented organs—is associated with 10-year all-cause mortality and recurrent MI [234].
Comorbidities and Pharmacological Influences
Psychosocial and nutritional factors significantly impact recovery. Comorbid major depressive disorder (MDD) is linked to worse outcomes after STEMI, but the use of selective serotonin reuptake inhibitors (SSRIs) at or prior to the event is associated with mortality outcomes that vary by follow-up duration (1 month to 3 years) [236]. Malnutrition, assessed by the CONUT score (threshold 5–12), is a potent predictor of in-hospital and 1-year mortality in elderly STEMI patients, even when adjusted for frailty [238]. In critically ill NSTEMI patients, severe obesity and inflammation (CRP >2 mg/L) have joint effects on both in-hospital and 10-year mortality [179]C. Regarding pre-admission medications, β-blocker use prior to the onset of cardiogenic shock (CS) may influence weaning success from venoarterial extracorporeal membrane oxygenation (V-A ECMO) [237].
Cardiogenic Shock and Advanced Support
Mortality in cardiogenic shock remains high, but structured regional networks (hub-and-spoke models) may improve outcomes through standardized care [240]. For patients requiring mechanical circulatory support, escalating from partial-support microaxial flow pumps (mAFP) to full-support devices prior to durable left ventricular assist device (dLVAD) implantation is a strategy used for refractory shock [239]C.
Emerging Therapies and Machine Learning
Secondary prevention research continues to evolve; however, the addition of the factor XI inhibitor asundexian to antiplatelet therapy did not demonstrate superiority over antiplatelet therapy alone for secondary stroke prevention in recent phase 3 trials [140]. To improve bedside prediction, interpretable machine learning models using routine laboratory and demographic variables have been validated to predict 1-year cardiac death after PCI with high accuracy [235]C.
| Biomarker/Index | Threshold/Category | Outcome Association |
|---|---|---|
| sLDLR | Highest Tertile | Increased CVD mortality (12.8-year) |
| CONUT Score | 5–12 (Malnourished) | Increased 1-year mortality in elderly |
| CRP | >2 mg/L | Increased 10-year mortality in critically ill |
| TyG Index | Higher values | Increased all-cause mortality |
| SHR | Dose-dependent | Increased in-hospital mortality |
Special Populations
- ▸Elevated angiography-derived microvascular resistance (AMR) and HbA1c are synergistic predictors of MACCE in diabetic STEMI patients.
- ▸Extended DAPT (24 months) is being evaluated for event-free patients with multivessel disease post-stenting.
- ▸Hypoalbuminemia (≤3.6 g/dL) is a predictor of MACE in elderly patients with atrial fibrillation.
- ▸Internet-delivered CBT is an emerging treatment for stress and anxiety in MINOCA and Takotsubo syndrome patients.
- ▸Sleep disorders in COPD patients significantly increase the risk of secondary cardiovascular events.
- ▸The TyG index is a valuable marker for predicting AMI risk and mortality in CAD patients.
Diabetes Mellitus and Metabolic Dysregulation
Patients with diabetes mellitus (DM) represent a high-risk subgroup following acute myocardial infarction (AMI), characterized by significant risk heterogeneity [233]. In patients with diabetic ST-segment elevation myocardial infarction (STEMI), the combination of elevated angiography-derived microvascular resistance (AMR) and high HbA1c levels jointly predicts adverse outcomes, including major adverse cardiovascular and cerebrovascular events (MACCEs) [178]. For those with non-ST-segment elevation myocardial infarction (NSTEMI) undergoing percutaneous coronary intervention (PCI), the hemoglobin glycation index (HGI) serves as a prognostic marker, where higher HGI has been associated with more favorable survival outcomes in specific cohorts [186].
Metabolic indices beyond glucose are also critical; the triglyceride-glucose (TyG) index is significantly associated with the risk of AMI and all-cause mortality in patients with coronary artery disease (CAD) [229]. Admission-based models utilizing routine variables have been developed to characterize 180-day mortality risk in diabetic AMI patients, providing prognostic information that may complement the GRACE score [233].
Obesity and Inflammation
In critically ill NSTEMI patients, severe obesity and systemic inflammation (measured via C-reactive protein [CRP]) have joint effects on mortality [179]C. Research indicates that while body mass index (BMI) is a factor, the incremental value of CRP (dichotomized at 2 mg/L) significantly improves risk stratification for both in-hospital and 10-year all-cause mortality [179]C.
Multivessel Coronary Artery Disease
Management of multivessel disease often involves complex antiplatelet strategies. In patients with multivessel CAD who remain event-free for 12 months after drug-eluting stent implantation, extending dual antiplatelet therapy (DAPT) with clopidogrel and aspirin for an additional 12 months (totaling 24 months) is a strategy currently under investigation to reduce long-term ischemic events [241].
MINOCA and Takotsubo Syndrome
Patients diagnosed with myocardial infarction with nonobstructive coronary arteries (MINOCA) or Takotsubo syndrome (TS) frequently experience poor mental health and reduced quality of life [243]. Internet-delivered cognitive behavioral therapy (iCBT) has been evaluated as a non-pharmacological intervention to reduce symptoms of stress (Perceived Stress Scale ≥25) and anxiety (HADS-A ≥8) in these populations [243].
Elderly Patients and Comorbidities
In elderly patients with non-valvular atrial fibrillation (AF), serum albumin (SA) levels serve as a prognostic indicator; levels ≤3.6 g/dL are associated with a higher occurrence of major adverse cardiovascular events (MACE), including non-fatal stroke and MI [250]. Additionally, new-onset atrial fibrillation (NOAF) following major surgeries like esophagectomy is associated with adverse cardiovascular outcomes over a 12-month period [248].
Chronic Obstructive Pulmonary Disease (COPD)
Patients with COPD and concurrent sleep disorders face an increased risk of adverse cardiovascular outcomes, including stroke and heart failure [245]. The biological pathways for this increased risk may include chronic intermittent hypoxia and systemic inflammation [245].
Critical Care and Supportive Interventions
Delirium and sleep disturbances are prevalent in the Cardiac Intensive Care Unit (CCU) following AMI [242]. Non-pharmacological interventions, such as head and facial massage combined with lavender oil aromatherapy, have been studied for their potential to improve sleep quality and reduce delirium severity [242]. For patients with non-reduced ejection fraction (LVEF ≥40%), the long-term administration of beta-blockers remains a subject of debate, as their efficacy in reducing MACE in this specific subgroup is less established than in those with reduced LVEF [244].
| Population | Marker/Threshold | Clinical Significance |
|---|---|---|
| Diabetic STEMI | AMR + HbA1c | Predicts MACCE [178] |
| Elderly (AF) | Serum Albumin ≤3.6 g/dL | Increased MACE risk [250] |
| NSTEMI (Critically Ill) | CRP >2 mg/L | Mortality risk stratification [179]C |
| MINOCA/Takotsubo | PSS ≥25 / HADS-A ≥8 | Threshold for iCBT intervention [243] |
| CAD Patients | TyG Index | Associated with AMI and mortality [229] |
Guidelines and Resources
- ▸The 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline is the current definitive North American standard for ACS management [153].
- ▸High-sensitivity troponin H0/H1 algorithms can facilitate early discharge in 75% of patients [157].
- ▸Radial access and drug-eluting stents are preferred for STEMI patients according to ESC 2017 standards [164].
- ▸Oxygen therapy is only indicated if saturation is <90% [164].
- ▸DAPT duration is dynamic and should be individualized based on ischemic vs. bleeding risk scores [168].
- ▸Cardiogenic shock classification (SCAI) is essential for staging and managing AMI complications [156].
- ▸Intravascular imaging is recommended to guide PCI in the 2024 CVIT consensus [154].
North American Clinical Guidelines
The management of acute coronary syndromes (ACS) has undergone significant evolution, culminating in the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes [153]. This comprehensive document integrates evidence since the 2013 STEMI and 2014 NSTEMI guidelines, effectively retiring the 2016 focused update on dual antiplatelet therapy (DAPT) [153]. For patients with stable ischemic heart disease, the American College of Physicians (ACP) and associated bodies provide a framework for diagnosis, emphasizing the grading of evidence to guide clinicians in identifying suspected coronary disease [159].
Specialized consensus statements address critical complications and unique scenarios. The SCAI clinical expert consensus (2019) provides a robust classification schema for cardiogenic shock, categorizing the disease state into stages to improve outcomes that had remained stagnant for 30 years [156]. During the COVID-19 pandemic, a joint position statement from SCAI, ACC, and ACEP was issued to maintain systematic AMI care while addressing the complexities of COVID-19-induced myocarditis and the risks to non-infected cardiovascular patients [155].
European and International Standards
The European Society of Cardiology (ESC) remains a primary authority, with the 2017 STEMI guidelines establishing radial artery access as the preferred site and favoring drug-eluting stents (DES) over bare-metal stents [164]. These guidelines also recommend complete revascularization during the index hospitalization and advise that oxygen therapy should only be initiated if oxygen saturation falls below 90% [164]. For NSTEMI, the 2015 ESC guidelines introduced the 1-hour diagnostic algorithm using high-sensitivity troponin (hs-cTn), which allows for the early discharge of approximately 75% of emergency patients [157][169].
In Japan, the CVIT 2024 expert consensus document reinforces primary PCI as the standard of care, even in cases of cardiogenic shock, and highlights that intravascular imaging should be considered to guide PCI (Class II recommendation) [154]. In India, the API expert consensus document addresses the rising incidence of CAD, emphasizing the role of drug-eluting stents and aggressive risk factor modification [171].
Diagnostic and Procedural Recommendations
Diagnostic protocols emphasize the use of high-sensitivity troponin assays as the first-line tool, utilizing H0/H3 or H0/H1 algorithms [157]. However, the H0/H1 algorithm is not suitable for patients who present very early after chest pain onset [157]. Pre-hospital management is critical; the Acute Cardiovascular Care Association (ACCA) emphasizes standardized transfer protocols for patients with chest pain or dyspnea [158].
Imaging guidelines from the EANM/ESC provide standards for radionuclide imaging to determine left and right ventricular ejection fractions (LVEF/RVEF) and volumes [162]. Echocardiography (transthoracic and transesophageal) is established as the cornerstone for identifying cardiac sources of embolism, which account for 15-30% of ischemic strokes [170].
Pharmacotherapy and DAPT Duration
Dual antiplatelet therapy (DAPT) duration is now determined by an individual's balance of ischemic versus bleeding risk rather than stent type [168]. The 2017 ESC focused update suggests DAPT duration can range from 1 to 36 months depending on this risk profile [168]. While aspirin remains a cornerstone for all symptomatic patients, beta-blockers must be used cautiously in the acute setting due to the risk of inducing cardiogenic shock [163]. For NSTEMI patients, while those presenting during "off-hours" may receive less aggressive initial treatment, data suggests their short-term outcomes are not necessarily worse than those presenting during regular hours [166].
| Recommendation | Standard | Reference |
|---|---|---|
| Access Site | Radial Artery (Preferred) | [164] |
| Stent Type | Drug-Eluting Stents (DES) | [164] |
| Oxygen Therapy | Only if SaO2 < 90% | [164] |
| Revascularization | Complete during index hospital stay | [164] |
| Thrombus Aspiration | Avoid routine use | [164] |
References
- [1]
Di Fusco SA, Matteucci A, Alonzo A et al.. “Beta-Blocker Therapy After Myocardial Infarction: A Systematic Review and Meta-Analysis of Contemporary Randomized Controlled Trials.” International journal of molecular sciences (2026). PMID: 41828582 ↗
L1aSR_MA_RCTCited in: Definition, Synonyms, and Classification - [2]
Yang Y, Liao M, Liu X et al.. “Prognostic Impact of Renin-Angiotensin System Inhibitors in Revascularized Patients with Acute Myocardial Infarction and Preserved or Mildly Reduced Ejection Fraction: A Retrospective Cohort Study.” Journal of clinical medicine (2026). PMID: 41976977 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [3]
Smidtslund P, Harjutsalo V, Thorn V et al.. “Comparison of incidence patterns and risk profiles of ST-elevation and non-ST-elevation myocardial infarction in type 1 diabetes in Finland: a nationwide cohort study.” The lancet. Diabetes & endocrinology (2026). PMID: 41871591 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification, Special Populations - [4]
Kryeziu B, Poniku A, Henein MY et al.. “Epidemiological 11-Year Dynamics Study of Acute Myocardial Infarction: A Cohort Study in a Country with a Transitional Healthcare System.” Global heart (2026). PMID: 41766718 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [5]
Lu G, Wang X, Wang X et al.. “Case Report: Rapid progression of inflammation-driven coronary artery lesions in a normolipidemic patient with ANCA-associated vasculitis complicated by Stanford type A aortic dissection.” Frontiers in immunology (2026). PMID: 41909680 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [6]
Khalaf Y, Atta S, Helal A et al.. “Survival Beyond the Odds: Twelve-Week Follow-Up After Conservative Management of Post-Infarction Ventricular Free Wall Rupture.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 41772389 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [7]
Vural A, Dolanbay T, Cumaoglu MO et al.. “Metabolic risk factors associated with premature myocardial infarction in adults ≤ 35 years: a case-control study.” BMC cardiovascular disorders (2026). PMID: 41776422 ↗
L3bCASE_CONTROLCited in: Definition, Synonyms, and Classification - [8]
Madandar E, Zarinfar Y, Namazi MH et al.. “Associations of Endothelial-Related lncRNAs with Early-Onset STEMI: A Case-Control Study.” Journal of cardiovascular translational research (2026). PMID: 41758284 ↗
L3bCASE_CONTROLCited in: Definition, Synonyms, and Classification - [9]
Chen S, Wang R, Ma J et al.. “Impact of a Prehospital Chest Pain Alert App-Mediated Prehospital-in-Hospital Coordination Model on Treatment Delays and Clinical Outcomes in Patients With ST-Elevation Myocardial Infarction: Protocol for a 4-Year Retrospective Real-World Cohort Study.” JMIR research protocols (2026). PMID: 41973638 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification, Prognosis and Long-term Outcomes, Special Populations - [10]
Zhang Y, Wang S, Fang Z et al.. “Predictive Performance of Serum Monomeric C-Reactive Protein for Major Adverse Cardiovascular Events in Patients With Acute ST-Segment Elevation Myocardial Infarction at One-Year Post-Discharge: A Retrospective Cohort Study.” British journal of hospital medicine (London, England : 2005) (2026). PMID: 41914002 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification, Special Populations - [11]
Zhao J, Hong H, Fanaroff A et al.. “Advancing In-Hospital Mortality Prediction for Acute Myocardial Infarction: an analysis from the American Heart Association Get-With-the-Guidelines Coronary Artery Disease Registry.” American heart journal (2026). PMID: 41990900 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [12]
Ughetto A, Schrage B, Fürholz M et al.. “Beyond the STEMI Paradigm: Expanding the Scope of microAxial Flow Pump in Cardiogenic Shock.” The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2026). PMID: 41966345 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [13]
Speckauskiene V, Meilutyte-Lukauskiene D, Cerapaite-Trusinskiene R et al.. “Prognostic utility of Killip classification in acute myocardial infarction: a retrospective cohort analysis in contemporary clinical practice.” European heart journal open (2026). PMID: 41958748 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [14]
Aleksova A, Janjusevic M, Marketou M et al.. “Charting individualized pathways: IGF-1 and vitamin D in guiding personalized medicine for residual risk after AMI.” Progress in cardiovascular diseases (2026). PMID: 41956273 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [15]
Graves JM, Waken RJ, Wang F et al.. “Acute Myocardial Infarction in Medicare Beneficiaries During and After the COVID-19 Pandemic.” JAMA network open (2026). PMID: 41920542 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Special Populations - [16]
Kim CH, Joh HS, Kim HK et al.. “Comparison of Clinical Outcomes Between Incomplete and Complete Revascularization in NSTEMI Patients With Multivessel Disease.” JACC. Asia (2026). PMID: 41920117 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [17]
Laffan J, Gao H, Street A et al.. “Outcomes according to timely or delayed primary percutaneous coronary intervention or fibrinolysis in a national registry of patients with ST-segment elevation myocardial infarction.” Open heart (2026). PMID: 41916670 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Prognosis and Long-term Outcomes, Special Populations - [18]
Lugo-Gavidia LM, Saucedo JF, Arias-Mendoza A et al.. “Implementing the GWTG-CAD Program in Mexico: Feasibility, Challenges and Lessons Learned for Acute and Secondary Prevention and Management.” Journal of the American Heart Association (2026). PMID: 41914361 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Special Populations - [19]
Zhao Y, Chen XY, Zhu GJ et al.. “Incremental prognostic value of left atrial strain for heart failure-related events following ST-Segment elevation myocardial infarction.” European journal of radiology (2026). PMID: 41894993 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Special Populations - [20]
Pozzessere P, Di Lauro M, Incantalupo F et al.. “Evaluating the Efficacy of CPS, HEART and TIMI Score in Emergency Department Patients with Non-Traumatic Chest Pain: A Pilot Study.” Medical sciences (Basel, Switzerland) (2026). PMID: 41892866 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Special Populations - [21]
Beske RP, Klein A, Jensen LO et al.. “Early clinical recovery in STEMI cardiogenic shock: insights from the DanGer shock trial.” European heart journal. Acute cardiovascular care (2026). PMID: 41873805 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [22]
Palmisano T, Bilchick K, Guarraia D. “Hemoglobin A1c is more predictive of type 1 myocardial infarction than low-density lipoprotein or body mass index.” Nutrition, metabolism, and cardiovascular diseases : NMCD (2026). PMID: 41864779 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [23]
Sharkey SW, Herman R, Witt DR et al.. “Performance of Artificial Intelligence-Powered ECG Analysis in Suspected ST-Segment Elevation Myocardial Infarction.” JACC. Advances (2026). PMID: 41863986 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [24]
Bilato C, Girardi G, Zuin M et al.. “Temporal trend in epidemiology and performance indicators of acute myocardial infarction: A 25 years population-based study.” International journal of cardiology (2026). PMID: 41861850 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [25]
Mavridis A, Viktorisson A, Leósdóttir M et al.. “Medication adherence after myocardial infarction: Predictors, mortality and cardiovascular outcomes.” Atherosclerosis (2026). PMID: 41856699 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Prognosis and Long-term Outcomes - [26]
Hu D, Wu D, Huang T et al.. “Monocyte-to-lymphocyte ratio as a predictor of left ventricular aneurysm in acute STEMI patients.” Frontiers in endocrinology (2025). PMID: 41847671 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [27]
Ahmadi-Beni M, Mokhtarian K, Mobini GR et al.. “Fasciola hepatica-Derived Proteins Shield the Heart From Type 2 Myocardial Infarction in Rats by Modulating Oxidative Stress and Inflammatory Imbalance: Insights Relevant to the Hygiene Hypothesis.” Oxidative medicine and cellular longevity (2026). PMID: 41823333 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [28]
Möser C, Prystupa K, Schön M et al.. “Cohort profile: The DIabetes and ST-segment Elevation Myocardial Infarction (DISTEMI) Study.” Cardiovascular diabetology (2026). PMID: 41821026 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [29]
Kuku KO, Lenselink C, Venema CS et al.. “Impact of Coronary Artery Disease Extent on GRACE Risk Score Prognostic Performance After ST-Segment-Elevation Myocardial Infarction.” Journal of the American Heart Association (2026). PMID: 41804884 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Prognosis and Long-term Outcomes - [30]
Zhang YK, Shao X, Hu ST et al.. “Development and Validation of a Prognostic Model for One-year Mortality in Older Adults with Acute Myocardial Infarction Incorporating Activities of Daily Living Impairment.” Clinical interventions in aging (2026). PMID: 41799377 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Prognosis and Long-term Outcomes - [31]
Morosato M, Gaspardone C, Romagnolo D et al.. “Left Main Spontaneous Coronary Artery Dissection: Clinical Features, Management, and Outcomes.” JACC. Cardiovascular interventions (2025). PMID: 40208153 ↗
L2aSR_OBSCited in: Etiology and Triggering Factors - [32]
O'Donoghue ML, Morrow DA, Vavere AL et al.. “Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial.” Nature medicine (2025). PMID: 40999229 ↗
L1bRCTCited in: Etiology and Triggering Factors - [33]
Gebert ZM, Kwiecinski J, Weir-McCall JR et al.. “Impact of diabetes mellitus on coronary artery plaque characteristics and outcomes in the SCOT-HEART trial.” Journal of cardiovascular computed tomography (2025). PMID: 39788814 ↗
L1bRCTCited in: Etiology and Triggering Factors - [34]
Kolossváry M, Lin A, Kwiecinski J et al.. “Coronary Plaque Radiomic Phenotypes Predict Fatal or Nonfatal Myocardial Infarction: Analysis of the SCOT-HEART Trial.” JACC. Cardiovascular imaging (2025). PMID: 39480364 ↗
L1bRCTCited in: Etiology and Triggering Factors - [35]
Nurmohamed NS, Min JK, Anthopolos R et al.. “Atherosclerosis quantification and cardiovascular risk: the ISCHEMIA trial.” European heart journal (2024). PMID: 39101625 ↗
L1bRCTCited in: Etiology and Triggering Factors - [36]
Rexhaj E, Bär S, Soria R et al.. “Effects of alirocumab on endothelial function and coronary atherosclerosis in myocardial infarction: A PACMAN-AMI randomized clinical trial substudy.” Atherosclerosis (2024). PMID: 38513436 ↗
L1bRCTCited in: Etiology and Triggering Factors - [37]
Hong XL, Loh YH, Li DB et al.. “Intracoronary administration of tenecteplase to prevent PCI-related myocardial infarction in patients with echo-attenuated coronary plaques: study protocol for a multicenter, prospective, randomized controlled trial.” Trials (2024). PMID: 39587685 ↗
L2bTRIAL_NONRANDOMCited in: Etiology and Triggering Factors - [38]
Zhao J, Chen Z, Yang J et al.. “Effect of KLF15-Mediated Circadian Rhythm on Myocardial Infarction: A Narrative Review.” International journal of molecular sciences (2025). PMID: 40429972 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [39]
Chaturvedi A, Gadela NV, Kalra K et al.. “Non-atherosclerotic coronary causes of myocardial infarction in women.” Progress in cardiovascular diseases (2025). PMID: 39880182 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [40]
Chapman AR, Taggart C, Boeddinghaus J et al.. “Type 2 myocardial infarction: challenges in diagnosis and treatment.” European heart journal (2025). PMID: 39658094 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [41]
Juhasz V, Charlier FT, Zhao TX et al.. “Targeting the adaptive immune continuum in atherosclerosis and post-MI injury.” Atherosclerosis (2024). PMID: 39546915 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [42]
Młynarska E, Czarnik W, Fularski P et al.. “From Atherosclerotic Plaque to Myocardial Infarction-The Leading Cause of Coronary Artery Occlusion.” International journal of molecular sciences (2024). PMID: 39000400 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [43]
Katz AE, Gupte T, Ganesh SK. “From Atherosclerosis to Spontaneous Coronary Artery Dissection: Defining a Clinical and Genetic Risk Spectrum for Myocardial Infarction.” Current atherosclerosis reports (2024). PMID: 38761354 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [44]
Schelemei P, Wagner E, Picard FSR et al.. “Macrophage mediators and mechanisms in cardiovascular disease.” FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2024). PMID: 38275140 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [45]
Wang W, Huang B. “Recurrent Chest Pain Due to Spontaneous Coronary Artery Dissection Diagnosed by Optical Coherence Tomography.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2025). PMID: 41077821 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [46]
Mori T, Aoyama H, Tanaka A et al.. “Detailed Visualization of the Dissected False Lumen Using Intravascular Ultrasound, Optical Coherence Tomography, and Angioscopy in a Young Man With Acute Myocardial Infarction Caused by Spontaneous Coronary Artery Dissection.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2025). PMID: 40437848 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [47]
Mumma BE, Kim JM, Rogers JH. “Chest Pain in the Setting of Acute Stress: A Tale of Two Women.” Clinical therapeutics (2024). PMID: 39578136 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors, Differential Diagnosis - [48]
Littmann L. “An unusual cause of giant T waves.” The American journal of emergency medicine (2024). PMID: 38839488 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [49]
Cojocaru PA, Țieranu ML, Piorescu MTL et al.. “Myocardical Infarction in Young Adults: Revisiting Risk Factors and Atherothrombotic Pathways.” Medicina (Kaunas, Lithuania) (2025). PMID: 41011006 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [50]
Imbesi A, Greco A, Capodanno D. “Anti-inflammatory strategies for patients with atherosclerotic coronary disease.” Expert review of cardiovascular therapy (2025). PMID: 40968010 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [51]
Sharpe EE, Rose CH, Tweet MS. “Obstetric anesthesia considerations in pregnancy-associated myocardial infarction: a focused review.” International journal of obstetric anesthesia (2024). PMID: 39227292 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [52]
McAlister C, Kang M, Alfadhel M et al.. “Thrombolysis in Spontaneous Coronary Artery Dissection-Angiographic Findings and Clinical Outcomes.” The Canadian journal of cardiology (2026). PMID: 41173456 ↗
L5OTHERCited in: Etiology and Triggering Factors - [53]
Geers J, Manral N, Park C et al.. “AI-quantified epicardial adipose tissue and prediction of future myocardial infarction in patients with cardiometabolic disease: a post-hoc analysis from the SCOT-HEART trial.” Cardiovascular diabetology (2025). PMID: 41126192 ↗
L5OTHERCited in: Etiology and Triggering Factors - [54]
Li J, Chen R, Zhou J et al.. “Effect of clonal hematopoiesis on plaque morphology and prognosis in patients with acute myocardial infarction.” Genome medicine (2025). PMID: 40855342 ↗
L5OTHERCited in: Etiology and Triggering Factors - [55]
Raphael CE, Sandoval Y, Beachey JD et al.. “Causes of Myocardial Infarction in Younger Patients: Troponin-Elevation in Persons ≤65 Years Old in Olmsted County.” Journal of the American College of Cardiology (2025). PMID: 40864006 ↗
L5OTHERCited in: Etiology and Triggering Factors - [56]
Stepanian A, Travers RJ, Tesfu A et al.. “Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke.” Circulation (2025). PMID: 40762051 ↗
L5OTHERCited in: Etiology and Triggering Factors - [57]
Sun Q, Wang S, Zeng M et al.. “Impact of Carrying DNMT3A or TET2 Mutations on Plaque Characteristics and Prognosis in Patients With STEMI Based on OCT.” Circulation. Cardiovascular imaging (2025). PMID: 40755316 ↗
L5OTHERCited in: Etiology and Triggering Factors - [58]
Biccirè FG, Fabbiocchi F, Gatto L et al.. “Long-Term Prognostic Impact of OCT-Derived High-Risk Plaque Features: Extended Follow-Up of the CLIMA Study.” JACC. Cardiovascular interventions (2025). PMID: 40500004 ↗
L5OTHERCited in: Etiology and Triggering Factors - [59]
Hirose T, Fujii K, Hashimoto K et al.. “Plaque rupture and calcified nodules: major contributors to out-of-hospital cardiac arrest in acute myocardial infarction.” Cardiovascular intervention and therapeutics (2025). PMID: 40478392 ↗
L5OTHERCited in: Etiology and Triggering Factors - [60]
Xu C, Yang ML, Kho PF et al.. “Cross-Ancestry Associations of Spontaneous Coronary Artery Dissection Genetic Risk With Coronary Atherosclerosis and Migraine Headache.” Journal of the American Heart Association (2025). PMID: 40357661 ↗
L5OTHERCited in: Etiology and Triggering Factors - [61]
Giangiacomi F, Popelier B, Lochy S et al.. “OPENing a new ECLECTIC approach to NSTEMI and cardiac arrest using ECG-less coronary computed tomography angiography. Study design and rationale of two prospective clinical studies.” Cardiovascular revascularization medicine : including molecular interventions (2026). PMID: 41314866 ↗
L2bTRIAL_NONRANDOMCited in: Differential Diagnosis - [62]
Raat W, Nees L, Vaes B. “Diagnostic accuracy of signs and symptoms in acute coronary syndrome and acute myocardial infarction.” Scandinavian journal of primary health care (2025). PMID: 39308022 ↗
L2aSR_OBSCited in: Differential Diagnosis - [63]
Kharawala A, Nagraj S, Setia G et al.. “Cardiac Critical Care of the Cardio-Obstetric Patient.” Journal of intensive care medicine (2026). PMID: 39819322 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [64]
Ricci F, Martini C, Scordo DM et al.. “ECG Patterns of Occlusion Myocardial Infarction: A Narrative Review.” Annals of emergency medicine (2025). PMID: 39818676 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [65]
Gamboa S, Shenvi C. “The great imitator: Hyperkalemia presenting with paralysis and ST segment elevations.” The American journal of emergency medicine (2026). PMID: 41274182 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [66]
Di Leo M, Vasumini N, Maida A et al.. “Cardiac magnetic resonance imaging in myocardial infarction with non-obstructive coronary arteries (MINOCA): current and evolving perspectives.” Expert review of cardiovascular therapy (2025). PMID: 41103008 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [67]
Ceriani E, Berra S, Agozzino F et al.. “ST-segment elevation in acute pericarditis and myocardial involvement: electrocardiographic and clinical profiling.” Open heart (2026). PMID: 41850763 ↗
L5OTHERCited in: Differential Diagnosis - [68]
Airaksinen KEJ, Teppo K, Vasankari T et al.. “Long Troponin T to Separate Troponin Elevations Among Patients With Atrial Fibrillation Versus Myocardial Infarction.” Journal of the American Heart Association (2026). PMID: 41757465 ↗
L5OTHERCited in: Differential Diagnosis - [69]
Zhou Y, Chen C, Li J et al.. “Identification and Validation of Differentially Expressed mRNAs From Peripheral Leukocytes for Acute Stanford Type A Aortic Dissection.” Journal of the American Heart Association (2025). PMID: 41378480 ↗
L5OTHERCited in: Differential Diagnosis - [70]
Li L, Liu Y, Wu Y et al.. “Comparison of the cardiac troponin I-cardiac troponin T-troponin C complex and cardiac troponin I and T in distinguishing myocardial infarction using a single sample at presentation.” Clinical chemistry and laboratory medicine (2026). PMID: 41213158 ↗
L5OTHERCited in: Differential Diagnosis - [71]
Andreß S, Melnic R, Christow H et al.. “Right-sided cardiogenic shock from acute pulmonary tumor thrombotic microangiopathy: a rare but deadly cardio-oncologic and metabolic emergency.” Clinical research in cardiology : official journal of the German Cardiac Society (2026). PMID: 40954305 ↗
L5OTHERCited in: Differential Diagnosis - [72]
Zhou P, Zhang J, Wu X et al.. “Differential diagnosis of acute myocardial infarction based on plasma Exosomal MicroRNA.” International journal of legal medicine (2026). PMID: 40850945 ↗
L5OTHERCited in: Differential Diagnosis - [73]
Snavely A, Jackson L, Hunter CJ et al.. “Differentiating Type 1 and Type 2 myocardial infarction using a machine learning algorithm and biomarkers.” The American journal of emergency medicine (2025). PMID: 40834835 ↗
L5OTHERCited in: Differential Diagnosis - [74]
Du Z, Hu H, Shen C et al.. “Right Ventricular Strain as a Key Feature in Interpretable Machine Learning for Identification of Takotsubo Syndrome: A Multicenter CMR-based Study.” Academic radiology (2025). PMID: 40404506 ↗
L5OTHERCited in: Differential Diagnosis - [75]
Sax DR, Warton EM, Mark DG et al.. “Emergency Department Triage Accuracy and Delays in Care for High-Risk Conditions.” JAMA network open (2025). PMID: 40314952 ↗
L5OTHERCited in: Differential Diagnosis - [76]
Yildiz M, Pico M, Henry TD et al.. “Sex Differences in Patients Presenting With ST-Segment Elevation Myocardial Infarction and Nonobstructive Coronary Arteries.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2025). PMID: 39906977 ↗
L5OTHERCited in: Differential Diagnosis - [77]
Wang L, Wu H, Wu C et al.. “A deep-learning system integrating electrocardiograms and laboratory indicators for diagnosing acute aortic dissection and acute myocardial infarction.” International journal of cardiology (2025). PMID: 39880045 ↗
L5OTHERCited in: Differential Diagnosis - [78]
Li L, Liu Y, Katrukha IA et al.. “Characterization of Cardiac Troponin Fragment Composition Reveals Potential for Differentiating Etiologies of Myocardial Injury.” Clinical chemistry (2025). PMID: 39697116 ↗
L5OTHERCited in: Differential Diagnosis - [79]
Araoz PA, Gadam S, Bhanushali AK et al.. “Triple Rule Out CT in the Emergency Department: Clinical Risk and Outcomes (Triple Rule Out in the Emergency Department).” Academic radiology (2025). PMID: 39658473 ↗
L5OTHERCited in: Differential Diagnosis - [80]
Airaksinen JKE, Tuominen T, Paana T et al.. “Novel troponin fragmentation assay to discriminate between Takotsubo syndrome and acute myocardial infarction.” European heart journal. Acute cardiovascular care (2024). PMID: 39422200 ↗
L5OTHERCited in: Differential Diagnosis - [81]
Son JH, Park JK, Bang JH et al.. “Exosomal miRNAs Differentiate Chronic Total Occlusion from Acute Myocardial Infarction.” International journal of molecular sciences (2024). PMID: 39337705 ↗
L5OTHERCited in: Differential Diagnosis - [82]
Seitz A, Dicpinigaitis AJ, Zhang C et al.. “Ischemic events are infrequent in patients with ovarian hyperstimulation syndrome.” Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2025). PMID: 39321946 ↗
L5OTHERCited in: Differential Diagnosis - [83]
Yakovlev S, Gvozdeva A. “Left Ventricular Pericardial Strangulation: A Diagnostic Challenge in Acute Coronary Syndrome.” Methodist DeBakey cardiovascular journal (2026). PMID: 41725857 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [84]
Bui-Thi HD, Vu VH, Nguyen KD et al.. “Successful management of protracted anaphylaxis-induced severe acute respiratory distress syndrome masquerading as non-ST elevation myocardial infarction: a rare case report.” BMC cardiovascular disorders (2026). PMID: 41606487 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [85]
Dewi IP, Damayanti KR, Anggitama AM et al.. “Tackling the ST elevation in leptospirosis: A double-edged sword between bleeding and thrombosis - A case report.” Narra J (2025). PMID: 40951499 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [86]
Lacaita PG, Feuchtner GM. “Ruptured coronary aneurysm with fatal bleeding: a tricky differential diagnosis.” The international journal of cardiovascular imaging (2025). PMID: 40261595 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [87]
Ying HL, Zhao H, Zhang C et al.. “Pitfalls of computed tomography angiography examination in veno-arterial extracorporeal membrane oxygenation patients: a case report of a patient with cardiac rupture.” Journal of cardiothoracic surgery (2024). PMID: 39736763 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [88]
Raizner AE. “Myocardial Infarction with Normal Coronary Arteries.” Methodist DeBakey cardiovascular journal (2024). PMID: 39525371 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [89]
Gao S, An R, Wang C. “Tracheopericardial fistula in lung cancer masquerading as acute myocardial infarction: a case report.” BMC pulmonary medicine (2024). PMID: 39449137 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [90]
Haberman D, Verma B, Abusnina W et al.. “Low- Versus High-capacity Impella for CS After AMI: A Systematic Review and Pooled Data Analysis.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 41507087 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [91]
Parlow S, Jung RG, Almoosawy SA et al.. “Prognostic Factors Among Patients Receiving Microaxial Flow Pump for Acute Myocardial Infarction-Related Cardiogenic Shock: A Systematic Review and Meta-Analysis.” Critical care medicine (2026). PMID: 41504526 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [92]
Scquizzato T, Grunau B, Fernando SM et al.. “Temporary mechanical circulatory support after return of spontaneous circulation following cardiac arrest: a systematic review and meta-analysis.” Resuscitation (2025). PMID: 41232590 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [93]
Obradovic D, Schulz L, Loncar G et al.. “Prognostic performance of cardiogenic shock 4 proteins prediction model in infarct-related cardiogenic shock.” ESC heart failure (2026). PMID: 41711227 ↗
L1bRCTCited in: Supportive Care and Complication Management, Prognosis and Long-term Outcomes - [94]
Sørensen R, Møller JE, Vandenbriele C et al.. “Bleeding in Patients With Infarct-Related Cardiogenic Shock: A DanGer Shock Substudy.” JACC. Cardiovascular interventions (2026). PMID: 41672689 ↗
L1bRCTCited in: Supportive Care and Complication Management, Prognosis and Long-term Outcomes - [95]
Jensen LO, Beske RP, Eiskjær H et al.. “Delay From First Symptoms in Patients Presenting With STEMI and Cardiogenic Shock: Insights From the DanGer Shock Trial.” Circulation. Cardiovascular interventions (2026). PMID: 41521915 ↗
L1bRCTCited in: Supportive Care and Complication Management - [96]
Kim MC, Ahn JH, Hyun DY et al.. “Complete revascularization timing in ST-segment elevation myocardial infarction and multivessel disease with heart failure: the OPTION-STEMI trial.” European heart journal (2026). PMID: 41493330 ↗
L1bRCTCited in: Supportive Care and Complication Management - [97]
Mangner N, Beske RP, Hassager C et al.. “Sex-Specific Microaxial Flow Pump Use and Outcomes in Infarct-Related Cardiogenic Shock in the DanGer Shock Trial.” Journal of the American College of Cardiology (2026). PMID: 41222528 ↗
L1bRCTCited in: Supportive Care and Complication Management - [98]
Nijveldt R, Maeng M, Beijnink CWH et al.. “Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction.” The New England journal of medicine (2026). PMID: 41159879 ↗
L1bRCTCited in: Supportive Care and Complication Management - [99]
Laborante R, Paglianiti DA, Elia S et al.. “Safety and efficacy of early initiation of mineralocorticoid receptor antagonist after an acute decompensated heart failure event or acute myocardial infarction with cardiac dysfunction: a meta-analysis of randomized clinical trials.” ESC heart failure (2026). PMID: 41712413 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [100]
Sheng Z, Chen B. “Differences in the characteristics and outcomes of STEMI versus NSTEMI cardiogenic shock: A systematic review and meta-analysis.” Medicine (2025). PMID: 41189239 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [101]
Deng L, Gao Y, Pan L et al.. “Free Triiodothyronine as a Biomarker for Ventricular Arrhythmia Following Myocardial Infarction: A Multicenter Prospective Cohort Study.” Clinical interventions in aging (2026). PMID: 41867325 ↗
L2bCOHORTCited in: Supportive Care and Complication Management, Special Populations - [102]
Israeli Hadar Y, Haim M, Tsaban G et al.. “Impact of late ventricular fibrillation on postdischarge 1-year mortality of patients presenting with acute myocardial infarction: a nationwide retrospective study.” BMJ open (2025). PMID: 41469077 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [103]
Kloosterman M, Smits KC, Stoks J et al.. “Computer-aided characterization of the arrhythmogenic substrate after myocardial infarction.” Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2026). PMID: 41512109 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [104]
Thiele H, Hassager C. “Cardiogenic Shock.” The New England journal of medicine (2026). PMID: 41467651 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [105]
Marcos-Garcés V, Bertolín-Boronat C, Merenciano-González H et al.. “Left Ventricular Remodeling After Myocardial Infarction-Pathophysiology, Diagnostic Approach and Management During Cardiac Rehabilitation.” International journal of molecular sciences (2025). PMID: 41303447 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [106]
Spaeth LD, Rahim M, Kochar A et al.. “Cardiogenic Shock and Temporary Mechanical Circulatory Support.” The Medical clinics of North America (2025). PMID: 41136064 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [107]
Boettger P, Preusse-Sondermann H, Sedighi J et al.. “Acute kidney injury as a prognostic determinant in cardiogenic shock: a cohort study.” Clinical and experimental nephrology (2026). PMID: 41225284 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [108]
Hassan AM, Aziz F, Tripolt NJ et al.. “Carbohydrate antigen 125 (CA125) following acute myocardial infarction: effects of empagliflozin and association with heart failure readouts in the EMMY trial.” Scientific reports (2025). PMID: 41430429 ↗
L1bRCTCited in: Supportive Care and Complication Management - [109]
Filipescu R, Collins SP, Radu RI et al.. “Therapeutic Advances in the Management of Cardiogenic Shock.” American journal of therapeutics (Unknown). PMID: 41543923 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [110]
Adi A, Jain R, Guru S et al.. “Antimicrobial Use in Acute Myocardial Infarction-Related Cardiogenic Shock.” Journal of the American Heart Association (2026). PMID: 41904804 ↗
L5OTHERCited in: Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Special Populations - [111]
Feng R, Hu L, Zhu Y et al.. “Association between TyG-related indices and in-hospital acute heart failure in patients with acute myocardial infarction after emergency percutaneous coronary intervention.” Frontiers in endocrinology (2026). PMID: 41869030 ↗
L5OTHERCited in: Supportive Care and Complication Management - [112]
Smyth D, Zhang L, Al-Khalaf M et al.. “Hematopoietic expression of cIAP2 drives inflammation and heart failure after myocardial infarction.” Nature cardiovascular research (2026). PMID: 41820671 ↗
L5OTHERCited in: Supportive Care and Complication Management - [113]
Wei Q, Zhou H, Sun J et al.. “SLC31A1 knockdown mitigates post-MI heart failure via regulation of copper metabolism.” Frontiers in immunology (2026). PMID: 41808820 ↗
L5OTHERCited in: Supportive Care and Complication Management - [114]
Wybraniec MT, Sufryd A, Cichoń M et al.. “Cardiogenic shock in the course of myocardial infarction: the results of the Shock-POL registry.” ESC heart failure (2026). PMID: 41746839 ↗
L5OTHERCited in: Supportive Care and Complication Management - [115]
Han T, Wen X, Guo Y et al.. “E3 ubiquitin ligase TRIM21-mediated K48-linked ubiquitination of ALDH2 rs671 mutant promotes adverse cardiac remodeling.” JCI insight (2026). PMID: 41734032 ↗
L5OTHERCited in: Supportive Care and Complication Management - [116]
Cheng M, Li L, Huang X et al.. “Linggui Zhugan Decoction mitigates post-myocardial infarction heart failure through modulation of cardiomyocyte F-actin cytoskeletal organization.” Phytomedicine : international journal of phytotherapy and phytopharmacology (2026). PMID: 41655544 ↗
L5OTHERCited in: Supportive Care and Complication Management - [117]
Zhou MM, Xu L, Huang DZ et al.. “KCNQ2 downregulation in left stellate ganglion neurons exacerbates malignant ventricular arrhythmias after myocardial infarction.” Journal of molecular and cellular cardiology (2026). PMID: 41654290 ↗
L5OTHERCited in: Supportive Care and Complication Management - [118]
Semedzhieva NE, Tsakova A, Lozanova V et al.. “17β-Estradiol Does Not Designate Non-Sex-Specific Early Ventricular Arrhythmia in Acute Myocardial Infarction, in Contrast to C-Reactive Protein.” International journal of molecular sciences (2026). PMID: 41596617 ↗
L5OTHERCited in: Supportive Care and Complication Management - [119]
Chiotis S, Giannopoulos G, Boulmpou A et al.. “Association of common risk factors with major adverse cardiac events and mortality in patients with MINOCA: A systematic review and meta-analysis.” International journal of cardiology (2026). PMID: 41655606 ↗
L2aSR_OBSCited in: Prognosis and Long-term Outcomes - [120]
Shen X, Zhang H, Li Z et al.. “Post-PCI Global QFR and Long-Term Outcomes in ACS: Findings From the FAVOR III China Trial.” JACC. Cardiovascular interventions (2026). PMID: 41986039 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes, Special Populations - [121]
Passo BD, Tonet E, Lanzilotti V et al.. “Consistent benefit of physiology-guided complete revascularization across the spectrum of frailty in older patients with myocardial infarction: a prespecified analysis of the FIRE trial.” Age and ageing (2026). PMID: 41965249 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes, Special Populations - [122]
Choi KH, Kang D, Kim W et al.. “Discontinuation of Beta-Blocker Therapy after Myocardial Infarction.” The New England journal of medicine (2026). PMID: 41910427 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes, Special Populations - [123]
Sans-Roselló J, Fernández-Peregrina E, Kuku KO et al.. “Timing of cardiogenic shock and clinical outcomes in takotsubo syndrome: A multicenter cohort study.” International journal of cardiology (2026). PMID: 41765143 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [124]
Madhavan MV, Gregson J, Redfors B et al.. “Spontaneous Myocardial Infarction After Left Main Revascularization: The EXCEL Trial.” Circulation (2026). PMID: 41664927 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes - [125]
Liu Y, Liu X, Sun D et al.. “Aspirin Combined With Ticagrelor or Clopidogrel in STEMI Patients With Diabetes Mellitus and Poor Glycemic Control Undergoing Primary PCI: A Multicenter Retrospective Cohort Study.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 41656976 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [126]
Heuts S, Pustjens TF, Lux Á et al.. “Probabilities of treatment effects in complete or culprit-only revascularization for NSTEMI: A Bayesian re-analysis of the SLIM trial.” American heart journal (2026). PMID: 41654213 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes - [127]
Zhao P, Li ZX, Jiang EL et al.. “Acute myocardial infarction following allogeneic hematopoietic stem cell transplantation: A national cohort study.” Cancer letters (2026). PMID: 41628833 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [128]
Huang DS, Fang CY, Hsueh SK et al.. “Predictors of Clinical Outcomes in Myocardial Infarction Patients Underwent Coronary Intervention With Rotational Atherectomy: A Single-Center Retrospective Study in Southern Taiwan.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 41623217 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [129]
Armstrong PW, Zheng Y, Welsh RC et al.. “Primary percutaneous coronary intervention within the first hour: Insights from early-treated patients with ST-elevation myocardial infarction.” American heart journal (2026). PMID: 41619999 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes - [130]
Wang B, Song Y, Fan Y et al.. “Association of Initial Laxative Strategy With Clinical Outcomes in Critically Ill Patients With Acute Myocardial Infarction: A Retrospective Cohort Study.” Cardiovascular therapeutics (2026). PMID: 41964389 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes, Special Populations - [131]
Zhou T, Yang K, Yang Y et al.. “Complete Blood Count-Derived Inflammation Indices to Predict 3-Year All-Cause Mortality in Patients With Diabetes and Acute Myocardial Infarction in Critical Care: Retrospective Cohort Study With Single-Center External Validation.” JMIR medical informatics (2026). PMID: 41818746 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes, Special Populations - [132]
Spadafora L, Bernardi M, Biondi-Zoccai G et al.. “GRACE score for risk stratification and completeness of revascularization in older patients with myocardial infarction.” Journal of cardiovascular medicine (Hagerstown, Md.) (2026). PMID: 41860766 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes, Special Populations - [133]
Zhao X, Chen R, Li J et al.. “Utility of Novel Lipid Parameters for Risk Stratification in Patients with Diabetes and STEMI-from a Prospective Study.” Vascular health and risk management (2026). PMID: 41877706 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes, Special Populations - [134]
Nyanga AF, Mohamed J, Msunza M et al.. “Performance of the Grace ACS Risk Score in Predicting in-Hospital and Six-Month Mortality in Patients with ACS: A Single Center Retrospective Cohort Study.” Vascular health and risk management (2026). PMID: 41736925 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [135]
Sundh J, Parker WAE, Oldgren J et al.. “Prognostic Value of Impaired Spirometry in Patients with Myocardial Infarction: A Longitudinal Study of Two European Cohorts.” International journal of chronic obstructive pulmonary disease (2026). PMID: 41947782 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes, Special Populations - [136]
Yarahmadi P, Hedlin H, Bates S et al.. “Survival After the First Myocardial Infarction in Older Women: A Prospective Cohort Analysis From the WHI.” Journal of the American Heart Association (2026). PMID: 41848053 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [137]
Dahiya G, Bohman JK, Tonna JE et al.. “Acid-Base Status During Venoarterial Extracorporeal Membrane Oxygenator Support in Patients With Cardiogenic Shock.” Journal of the American Heart Association (2026). PMID: 41823232 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [138]
Elbadawi A, Chen A, Wojdyla D et al.. “Contemporary Trends, Characteristics, and Outcomes of Patients Undergoing Percutaneous Coronary Intervention for Stent Thrombosis.” JACC. Cardiovascular interventions (2026). PMID: 41813273 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [139]
Kwon Y, Kim N, Kim DH et al.. “Long-Term Clinical Outcomes of Acute Myocardial Infarction Based on Institutional Experience With IVUS.” Journal of the American Heart Association (2026). PMID: 41757462 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [140]
Sharma M, Dong Q, Hirano T et al.. “Asundexian for Secondary Stroke Prevention.” The New England journal of medicine (2026). PMID: 41985132 ↗
L1bRCTCited in: Special Populations - [141]
Delewi R, Aarts HM, Broeze GM et al.. “Deferral of percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation (PRO-TAVI): an investigator-initiated, multicentre, open-label, non-inferiority, randomised controlled trial.” Lancet (London, England) (2026). PMID: 41921523 ↗
L1bRCTCited in: Special Populations - [142]
Kang J, Park S, Yang HM et al.. “Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention: 10-year follow-up of the HOST-EXAM trial.” Lancet (London, England) (2026). PMID: 41921522 ↗
L1bRCTCited in: Special Populations - [143]
Marcadenti A, Bersch-Ferreira AC, Vieira Machado RH et al.. “Supplementation with mixed nuts does not improve inflammatory biomarkers or dietary inflammatory potential in post-myocardial infarction: a secondary analysis of the DICA-NUTS trial.” Nutrition, metabolism, and cardiovascular diseases : NMCD (2026). PMID: 41856832 ↗
L1bRCTCited in: Special Populations - [144]
Sundqvist MO, Wärme J, Hjort M et al.. “Helicobacter pylori, Inflammation, and Long-Term Outcome in Patients With Acute Myocardial Infarction: A Prospective Cohort Study.” Helicobacter (2026). PMID: 41834132 ↗
L2bCOHORTCited in: Special Populations - [145]
Asadi N, Azarbarzin M, Salmani F. “The effect of early mobilization program on changes in hemodynamic symptoms in patients with acute myocardial infarction.” Journal of bodywork and movement therapies (2026). PMID: 41927220 ↗
L1bRCTCited in: Special Populations - [146]
Wang H, Chou E, Robinson RD et al.. “Federated Meta-Analysis of HEART Score Performance for Emergency Department Chest Pain.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2026). PMID: 41943236 ↗
L2aSR_OBSCited in: Special Populations - [147]
Turchin A, Shubina M, Morrison FJ et al.. “Cumulative excess weight exposure over time and cardiovascular risk: A prospective cohort study.” PloS one (2026). PMID: 41950162 ↗
L2bCOHORTCited in: Special Populations - [148]
Nesova A, Vorobeva D, Ryabov V. “Impact of the risk-treatment paradox on in-hospital and long-term outcomes in patients with very high-risk non-ST-elevation acute coronary syndrome.” The Indian journal of medical research (2026). PMID: 41934433 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [149]
Shen YC, Sarkar N, Hsia RY. “Community-Level Procedure Volume and Patient Health Profiles Following PCI-Capable Facility Openings.” JAMA network open (2026). PMID: 41910975 ↗
L5OTHERCited in: Special Populations - [150]
Cars T, Gustafsson S, Chan Q et al.. “Methodological Challenges of Emulating a Target Trial to Assess Effectiveness of Timing of PCSK9 Inhibitor Treatment Initiation Post Myocardial Infarction.” Pharmacoepidemiology and drug safety (2026). PMID: 41902372 ↗
L5OTHERCited in: Special Populations - [151]
Chen Y, Chang A, Cheng F et al.. “A nomogram for predicting in-hospital death in a multinational cohort of patients with takotsubo syndrome.” European journal of clinical investigation (2026). PMID: 41888991 ↗
L5OTHERCited in: Special Populations - [152]
Ozaki Y, Tobe A, Onuma Y et al.. “CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2026.” Cardiovascular intervention and therapeutics (2026). PMID: 41749019 ↗
L1cGUIDELINECited in: Guidelines and Resources - [153]
Rao SV, O'Donoghue ML, Ruel M et al.. “2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Circulation (2025). PMID: 40014670 ↗
L1cGUIDELINECited in: Guidelines and Resources - [154]
Ozaki Y, Tobe A, Onuma Y et al.. “CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2024.” Cardiovascular intervention and therapeutics (2024). PMID: 39302533 ↗
L1cGUIDELINECited in: Guidelines and Resources - [155]
Mahmud E, Dauerman HL, Welt FGP et al.. “Management of Acute Myocardial Infarction During the COVID-19 Pandemic: A Position Statement From the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP).” Journal of the American College of Cardiology (2020). PMID: 32330544 ↗
L1cGUIDELINECited in: Guidelines and Resources - [156]
Baran DA, Grines CL, Bailey S et al.. “SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2019). PMID: 31104355 ↗
L1cGUIDELINECited in: Guidelines and Resources - [157]
Charpentier S, Chenevier-Gobeaux C. “[2015 ESC guidelines: 1-hour rule-out and rule-in of acute myocardial infarction with high-sensitive troponin T].” Presse medicale (Paris, France : 1983) (2016). PMID: 27374265 ↗
L1cGUIDELINECited in: Guidelines and Resources - [158]
Beygui F, Castren M, Brunetti ND et al.. “Pre-hospital management of patients with chest pain and/or dyspnoea of cardiac origin. A position paper of the Acute Cardiovascular Care Association (ACCA) of the ESC.” European heart journal. Acute cardiovascular care (2020). PMID: 26315695 ↗
L1cGUIDELINECited in: Guidelines and Resources - [159]
Qaseem A, Fihn SD, Williams S et al.. “Diagnosis of stable ischemic heart disease: summary of a clinical practice guideline from the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons.” Annals of internal medicine (2012). PMID: 23165664 ↗
L1cGUIDELINECited in: Guidelines and Resources - [160]
George JC, Dangas GD. “2009 Focused updates to guidelines in ST-elevation myocardial infarction and percutaneous coronary intervention: application to interventional cardiology.” JACC. Cardiovascular interventions (2010). PMID: 20170887 ↗
L1cGUIDELINECited in: Guidelines and Resources - [161]
Pollack CV, Antman EM, Hollander JE. “2007 focused update to the ACC/AHA guidelines for the management of patients with ST-segment elevation myocardial infarction: implications for emergency department practice.” Annals of emergency medicine (2008). PMID: 18519158 ↗
L1cGUIDELINECited in: Guidelines and Resources - [162]
Hesse B, Lindhardt TB, Acampa W et al.. “EANM/ESC guidelines for radionuclide imaging of cardiac function.” European journal of nuclear medicine and molecular imaging (2008). PMID: 18224320 ↗
L1cGUIDELINECited in: Guidelines and Resources - [163]
Campbell-Scherer DL, Green LA. “ACC/AHA guideline update for the management of ST-segment elevation myocardial infarction.” American family physician (2009). PMID: 19530638 ↗
L1cGUIDELINECited in: Guidelines and Resources - [164]
Thiele H, Desch S, de Waha S. “[Acute myocardial infarction in patients with ST-segment elevation myocardial infarction : ESC guidelines 2017].” Herz (2017). PMID: 29119223 ↗
L1cGUIDELINECited in: Guidelines and Resources - [165]
Schäfer A, Bauersachs J. “[Focused update on dual antiplatelet treatment : ESC guidelines 2017].” Herz (2017). PMID: 29043405 ↗
L1cGUIDELINECited in: Guidelines and Resources - [166]
Pollack CV, Hollander JE, Chen AY et al.. “Non-ST-elevation myocardial infarction patients who present during off hours have higher risk profiles and are treated less aggressively, but their outcomes are not worse: a report from Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation of the ACC/AHA Guidelines CRUSADE initiative.” Critical pathways in cardiology (2009). PMID: 19258835 ↗
L1cGUIDELINECited in: Guidelines and Resources - [167]
. “[Guidelines of the American College of Cardiology/American Heart Association 2007 for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. Part VI].” Kardiologiia (2008). PMID: 18991825 ↗
L1cGUIDELINECited in: Guidelines and Resources - [168]
Massberg S, Polzin A. “[Update ESC-Guideline 2017: Dual Antiplatelet Therapy].” Deutsche medizinische Wochenschrift (1946) (2018). PMID: 30060279 ↗
L1cGUIDELINECited in: Guidelines and Resources - [169]
Hochholzer W, Neumann FJ. “[The new 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation].” Deutsche medizinische Wochenschrift (1946) (2016). PMID: 27254627 ↗
L1cGUIDELINECited in: Guidelines and Resources - [170]
Pepi M, Evangelista A, Nihoyannopoulos P et al.. “Recommendations for echocardiography use in the diagnosis and management of cardiac sources of embolism: European Association of Echocardiography (EAE) (a registered branch of the ESC).” European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology (2010). PMID: 20702884 ↗
L1cGUIDELINECited in: Guidelines and Resources - [171]
. “API expert consensus document on management of ischemic heart disease.” The Journal of the Association of Physicians of India (2006). PMID: 16909697 ↗
L1cGUIDELINECited in: Guidelines and Resources - [172]
Mahler SA, Ashburn NP, Villenthi A et al.. “Validation of a 0/2-Hour Point-Of-Care High Sensitivity Troponin Algorithm: A Multisite US Study.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2026). PMID: 42470147 ↗
L2bCited in: Definition, Synonyms, and Classification - [173]
Garrouste V, Guerineau A, Guenezan J et al.. “External Validation of the SCARE Score for Predicting Acute Myocardial Infarction in Patients Calling Emergency Medical Communication Centers: A Prospective Multicenter Study.” Prehospital emergency care (2026). PMID: 42213793 ↗
L2bCited in: Definition, Synonyms, and Classification - [174]
Alasmary MY, Almalki MJ, Almalki FH et al.. “Interleukin-6 Inhibition for Patients with Acute Myocardial Infarction: A Systematic Review and Meta-Analysis.” Saudi medical journal (2026). PMID: 42293710 ↗
L1aCited in: Definition, Synonyms, and Classification - [175]
Shlyakhover VE, Rozenbaum Z, Bruoha S. “Superimposed Takotsubo syndrome and acute myocardial infarction: a systematic review and pooled analysis of published cases.” International journal of cardiology. Heart & vasculature (2026). PMID: 42327959 ↗
L2aCited in: Definition, Synonyms, and Classification - [176]
Gupta MD, Kunal S, Girish MP et al.. “Comparison of ASCVD Risk Prediction Models in STEMI: Insights From a South Asian Cohort.” JACC. Asia (2026). PMID: 42470426 ↗
L3bCited in: Definition, Synonyms, and Classification - [177]
Mallol-Simmonds M, Rojas CG, Cañete Palta I et al.. “Depressive symptoms and health-related quality of life following acute myocardial infarction.” Frontiers in cardiovascular medicine (2026). PMID: 42445537 ↗
L3bCited in: Definition, Synonyms, and Classification - [178]
Gao S, Wang Y, Wang J et al.. “Elevated angiography-derived microvascular resistance and HbA1c levels jointly predict adverse outcomes in patients with diabetic STEMI: a multicenter retrospective cohort study.” Frontiers in endocrinology (2026). PMID: 42440617 ↗
L3bCited in: Definition, Synonyms, and Classification - [179]
Li Y, Wang Y, Lu P et al.. “Joint effects of severe obesity and inflammation on mortality in critically ill non-ST-segment elevation myocardial infarction patients: a cohort study with external validation.” Frontiers in endocrinology (2026). PMID: 42422429 ↗
L4Cited in: Definition, Synonyms, and Classification - [180]
Yu H, Qi S, Tian G. “The predictive value of NT-proBNP/ALB ratio for in-hospital pericardial effusion in young acute myocardial infarction patients.” Frontiers in cardiovascular medicine (2026). PMID: 42422178 ↗
L3bCited in: Definition, Synonyms, and Classification - [181]
Wrenn JO, Behrens M, Hershey MS et al.. “Large Language Model Summarization of Physician-to-Physician Calls for Interhospital Transfer of Patients With ST-Elevation Myocardial Infarction: Observational Study.” Journal of medical Internet research (2026). PMID: 42348906 ↗
L3bCited in: Definition, Synonyms, and Classification - [182]
Schwab M, Pamminger M, Kremser C et al.. “Association of Deep Learning-based Myocardial Infarction Size Quantification in Cardiac MRI with Cardiac Biomarker Levels.” Radiology. Cardiothoracic imaging (2026). PMID: 42347575 ↗
L3bCited in: Definition, Synonyms, and Classification - [183]
Yang Z, Liu Z, Xu Y et al.. “Serum LRG1 as a non-invasive biomarker for identifying complex coronary anatomy in pre-angiography risk stratification.” Frontiers in cardiovascular medicine (2026). PMID: 42338730 ↗
L3bCited in: Definition, Synonyms, and Classification - [184]
Wong HJ, Teo FJJ, Yau CE et al.. “Prognosis of patients with ST-elevation myocardial infarction presenting to the emergency department without chest pain: a retrospective nationwide cohort study.” Heart (British Cardiac Society) (2026). PMID: 42315345 ↗
L3bCited in: Definition, Synonyms, and Classification - [185]
Ninla-Aesong P, Sanakus S, Phonphet C et al.. “CBC-Derived Inflammatory Indices and Myocardial Injury Severity at Presentation in Acute Myocardial Infarction: Association and Discriminative Performance.” Journal of clinical medicine (2026). PMID: 42279258 ↗
L3bCited in: Definition, Synonyms, and Classification - [186]
Jiang H, Zhao Y, Zhao Y et al.. “Association between hemoglobin glycation index and all-cause mortality in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.” Frontiers in endocrinology (2026). PMID: 42267308 ↗
L3bCited in: Definition, Synonyms, and Classification - [187]
Chen BH, Li SL, Xiang JY et al.. “AI-based Histologic Heterogeneity of Microvascular Obstruction at Cardiac MRI for Predicting MACEs: A Multicenter Study.” Radiology (2026). PMID: 42227866 ↗
L3bCited in: Definition, Synonyms, and Classification - [188]
Mantilla Pérez B, Hurtado-Ortiz A, López J et al.. “Health-related quality of life after acute myocardial infarction and one-year clinical outcomes: A prospective cohort study.” International journal of cardiology. Cardiovascular risk and prevention (2026). PMID: 42472246 ↗
L2bCited in: Definition, Synonyms, and Classification - [189]
Kaya AF, Ayhan G, Can V et al.. “An Inflammation-renal composite approach to predict contrast-induced nephropathy in acute myocardial infarction.” International journal of cardiology. Cardiovascular risk and prevention (2026). PMID: 42434342 ↗
L2bCited in: Definition, Synonyms, and Classification - [190]
Stipčević M, Jurin I, Knežević Praveček M et al.. “Psychological Burden and Psychosocial Stress in Younger and Middle-Aged Women with Prior Myocardial Infarction.” Medicina (Kaunas, Lithuania) (2026). PMID: 42356095 ↗
L2bCited in: Definition, Synonyms, and Classification - [191]
Wang F, Ning M, Liu Y. “Prognostic value of X-box binding protein 1 and phospholipase A2 in myocardial injury after ST-segment elevation myocardial infarction: a prospective observational study.” Journal of cardiothoracic surgery (2026). PMID: 42289708 ↗
L2bCited in: Definition, Synonyms, and Classification - [192]
Gorog DA. “New approaches to preventing venous thromboembolism, prognostication in stroke and myocardial infarction, and antiplatelet therapy after spontaneous coronary artery dissection.” Journal of thrombosis and thrombolysis (2025). PMID: 40569553 ↗
L1bCited in: Etiology and Triggering Factors - [193]
Li J, Chen R, Zhao X et al.. “Circulating and Regional Matrix Gla Protein Indicating Plaque Calcification and Prognosis of Patients with ST-Segment Elevation Myocardial Infarction.” Thrombosis and haemostasis (2025). PMID: 40409299 ↗
L2bCited in: Etiology and Triggering Factors - [194]
Maaniitty T, Bär S, Bax JJ et al.. “Quantitative Coronary Atherosclerotic Plaque Burden From CCTA and the Benefit From Lipid-Lowering Medication.” Circulation. Cardiovascular imaging (2026). PMID: 41937634 ↗
L3bCited in: Etiology and Triggering Factors - [195]
Liu X, Wang B, Hao W et al.. “Association of Obstructive Sleep Apnea and Nocturnal Hypoxemia With the Circadian Rhythm of Myocardial Infarction.” Journal of the American Heart Association (2025). PMID: 39868516 ↗
L3bCited in: Etiology and Triggering Factors - [196]
Lu ZF, Cao Y, Abrol S et al.. “Predictive value of plaque features quantified by coronary CT angiography for periprocedural myocardial infarction in Non-ST-Segment elevation acute coronary syndrome.” The international journal of cardiovascular imaging (2025). PMID: 41233700 ↗
L2bCited in: Etiology and Triggering Factors - [197]
Chaturvedi A, Garcia-Garcia HM, Cellamare M et al.. “Outcomes of Primary Percutaneous Intervention for ST-Segment Elevation Myocardial Infarction With Versus Without Spontaneous Coronary Artery Dissection.” The American journal of cardiology (2025). PMID: 40107333 ↗
L2bCited in: Etiology and Triggering Factors - [198]
Wang S, Luo X, Hu S et al.. “Plaque erosion risk and JAK2 V617F variant.” European heart journal (2025). PMID: 40053703 ↗
L3bCited in: Etiology and Triggering Factors - [199]
Hikino K, Koyama S, Ito K et al.. “RNF213 Variants, Vasospastic Angina, and Risk of Fatal Myocardial Infarction.” JAMA cardiology (2024). PMID: 38888930 ↗
L3bCited in: Etiology and Triggering Factors - [200]
Murphy BM, Rogerson MC, Iismaa SE et al.. “Attitudes to and Attendance at Cardiac Rehabilitation After Spontaneous Coronary Artery Dissection.” Journal of cardiopulmonary rehabilitation and prevention (2025). PMID: 40257821 ↗
L3bCited in: Etiology and Triggering Factors - [201]
Kaddoura R, Mahmoud YA, Nasrallah D et al.. “Impact of cardiogenic shock on outcomes in patients with spontaneous coronary artery dissection: a systematic review and meta-analysis.” Panminerva medica (2026). PMID: 41925733 ↗
L2aCited in: Etiology and Triggering Factors - [202]
Budassi S, Biccirè FG, Gatto L et al.. “Independent role of atherosclerotic plaque composition and extension in predicting the risk of cardiac events: a CLIMA substudy.” The international journal of cardiovascular imaging (2024). PMID: 39432135 ↗
L3bCited in: Etiology and Triggering Factors - [203]
Schönbeck H, Björkelund A, Møller ES et al.. “A missed diagnosis of acute aortic syndrome is associated with ischaemic ECG changes and an initial suspicion of myocardial infarction: a retrospective observational study.” BMC emergency medicine (2025). PMID: 41315990 ↗
L3bCited in: Differential Diagnosis - [204]
Lindahl B, Thurston AJ, Tew YY et al.. “Change in cardiac troponin T to differentiate acute from chronic myocardial injury in the Emergency Department.” Clinical biochemistry (2025). PMID: 41241321 ↗
L2bCited in: Differential Diagnosis - [205]
Recchioni T, Manzi G, Caputo A et al.. “Sodium nitroprusside: A comprehensive systematic review of its role across various clinical settings.” Vascular pharmacology (2026). PMID: 41903872 ↗
L1aCited in: Differential Diagnosis - [206]
Pernigo M, Berti M, Renga EM et al.. “Enhancing echocardiographic diagnosis of typical Takotsubo syndrome: validation of IAR and ILAR indexes.” Journal of cardiovascular medicine (Hagerstown, Md.) (2026). PMID: 42349394 ↗
L3bCited in: Differential Diagnosis - [207]
Lin H, Sun Q, Yao W et al.. “Fear of movement and its associated psychosocial factors in patients with acute cardiovascular disease: a retrospective cohort study.” BMC cardiovascular disorders (2026). PMID: 41975277 ↗
L3bCited in: Differential Diagnosis - [208]
Puchongmart C, Lorlowhakarn K, Thiravetyan B et al.. “In-hospital outcomes associated with extracorporeal membrane oxygenation in Takotsubo cardiomyopathy with cardiogenic shock: a propensity-matched analysis of a national cohort.” Journal of cardiovascular medicine (Hagerstown, Md.) (2026). PMID: 41703407 ↗
L3bCited in: Differential Diagnosis - [209]
Huang Q, Zhao P, He Y et al.. “Multiparametric integration of cardiac markers in differentiating myocardial infarction with non-obstructive coronary arteries: LASSO regression.” Heart & lung : the journal of critical care (2025). PMID: 41135216 ↗
L3bCited in: Differential Diagnosis - [210]
Mele M, Mautone F, Ragnatela I et al.. “Biomarker profiles that differentiate type-1 and type 2 myocardial infarction.” Heart & lung : the journal of critical care (2025). PMID: 39752808 ↗
L3bCited in: Differential Diagnosis - [211]
Ripon RH, Zahin H, Noman AA et al.. “CDK7 as a Potential Exploratory Biomarker for Distinguishing Acute Myocardial Infarction Subtypes via DDR Pathways: Evidence From a Bangladeshi Cohort.” Clinical cardiology (2026). PMID: 42267702 ↗
L3bCited in: Differential Diagnosis - [212]
Huang M, Lin L, Fan XX et al.. “Development of a machine-learning based diagnosis procedure to distinguish aortic dissection from non-ST-elevation myocardial infarction.” BMC medical informatics and decision making (2026). PMID: 41882701 ↗
L5Cited in: Differential Diagnosis - [213]
Diercks D, Cao M, McHugh M et al.. “Evaluation and management of chest pain from cardiovascular causes in female patients.” BMJ (Clinical research ed.) (2026). PMID: 41617253 ↗
L5Cited in: Differential Diagnosis - [214]
Shen Y, Guo X, Zeng C et al.. “Varenicline and Ventricular Ectopy After Myocardial Infarction: A Randomized Phase 2 Study.” Journal of the American College of Cardiology (2026). PMID: 41778949 ↗
L2bCited in: Supportive Care and Complication Management - [215]
Jøns C, Søgaard P, Smilde T et al.. “Pitfalls in the reporting of clinical events in unblinded device trials: analysing performance bias in the BIO|GUARD-MI trial.” Trials (2026). PMID: 42129909 ↗
L1bCited in: Supportive Care and Complication Management - [216]
Alasnag M, Asiri A, Alrahbi H et al.. “National Heart Center - Saudi Health Council Acute Myocardial Infarction-Related Cardiogenic Shock Consensus Document.” Saudi medical journal (2026). PMID: 42238290 ↗
L1cCited in: Supportive Care and Complication Management - [217]
Patail H, Sharma T, Chand S et al.. “The Role of Mechanical Circulatory Support in Acute Myocardial Infarction Complicated by Cardiogenic Shock-Part Two: Getting with the Guidelines and the Future ahead.” Interventional cardiology clinics (2026). PMID: 42209066 ↗
L1bCited in: Supportive Care and Complication Management - [218]
Franco D, Belohlavek J, Rob D et al.. “Impact of cardiac arrest in patients with cardiogenic shock due to ST-elevation myocardial infarction.” Resuscitation (2026). PMID: 42019600 ↗
L3bCited in: Supportive Care and Complication Management - [219]
Fujimoto H, Komiyama K, Kodera S et al.. “Impella in killip class IV acute myocardial infarction complicated by pulseless ventricular arrhythmia.” Cardiovascular intervention and therapeutics (2026). PMID: 41904306 ↗
L3bCited in: Supportive Care and Complication Management - [220]
Elhadad A, El Zouhayri O, Silvain J et al.. “Efficacy and Safety of Intravenous Antiplatelet Therapy in Acute Myocardial Infarction With Cardiogenic Shock.” JACC. Cardiovascular interventions (2026). PMID: 41672691 ↗
L3bCited in: Supportive Care and Complication Management - [221]
Daoulah A, M Ladna J, Arabi A et al.. “Postangiography Prediction of Renal Replacement Therapy in Acute Myocardial Infarction-Related Cardiogenic Shock: Least Absolute Shrinkage and Selection Operator Nomogram Development and Validation.” JMIR cardio (2026). PMID: 42160715 ↗
L3bCited in: Supportive Care and Complication Management - [222]
Liu T, Meng Z, Li D et al.. “The association between glycemic variability and atrial fibrillation/in-hospital mortality in white and non-white patients with acute myocardial infarction: A retrospective cohort study.” Journal of the National Medical Association (2026). PMID: 42103517 ↗
L3bCited in: Supportive Care and Complication Management - [223]
Ammoury C, Ramu SK, Rajendran J et al.. “Timing of New-Onset Atrial Fibrillation After Myocardial Infarction: Prognostic Impact and Associated Clinical Characteristics.” The American journal of cardiology (2026). PMID: 42069282 ↗
L3bCited in: Supportive Care and Complication Management - [224]
Li H, Ma Y, Su Y. “Initial intra-aortic balloon pump versus Impella support strategies and short-term outcomes in acute myocardial infarction complicated by cardiogenic shock: a MIMIC-IV cohort study.” BMC cardiovascular disorders (2026). PMID: 42032454 ↗
L4Cited in: Supportive Care and Complication Management - [225]
Todurov M, Todurov B, Mokryk I et al.. “Impact of concomitant intra-aortic balloon pump support on outcomes in patients with acute myocardial infarction-related cardiogenic shock undergoing percutaneous coronary intervention with veno-arterial ECMO: a propensity-matched analysis.” BMC cardiovascular disorders (2026). PMID: 41922989 ↗
L3bCited in: Supportive Care and Complication Management - [226]
Rubino F, Mossop H, Ripley DP et al.. “Invasive vs Conservative Strategy for Frail Older Patients With Myocardial Infarction: A Secondary Analysis of the SENIOR-RITA Randomized Clinical Trial.” JAMA network open (2026). PMID: 42012832 ↗
L1bCited in: Prognosis and Long-term Outcomes - [227]
Ratcovich H, Holmvang L, Sadjadieh G et al.. “Percutaneous Coronary Intervention in Frail Patients Undergoing Transcatheter Aortic Valve Replacement: A NOTION-3 Substudy.” JACC. Cardiovascular interventions (2026). PMID: 41986033 ↗
L1bCited in: Prognosis and Long-term Outcomes - [228]
Sarti A, Verardi FM, Cavazza C et al.. “Diabetes does not attenuate the benefit of physiology-guided complete revascularization in older patients with myocardial infarction.” Cardiovascular diabetology (2026). PMID: 41981421 ↗
L1bCited in: Prognosis and Long-term Outcomes - [229]
Wang Y, Zeng C, Huang YL et al.. “The association of triglyceride-glucose index with acute myocardial infarction and all-cause mortality in patients with coronary artery disease stratified by acute myocardial infarction status: a large-scale retrospective cohort study from South China.” BMJ open (2026). PMID: 42276806 ↗
L2bCited in: Prognosis and Long-term Outcomes - [230]
Miao Y, Shen L, Wang L et al.. “Echocardiographic grading for long-term mortality risk stratification after first-time ST-segment elevation myocardial infarction: a multicentre cohort study.” BMJ open (2026). PMID: 42014156 ↗
L2bCited in: Prognosis and Long-term Outcomes - [231]
Kim S, Jun HJ, Jo G et al.. “Associations of plasma level of soluble LDL receptor with cardiovascular events and mortality in a large prospective cohort study.” Lipids in health and disease (2026). PMID: 41963945 ↗
L2bCited in: Prognosis and Long-term Outcomes - [232]
Wang W, Li Q, Shu L et al.. “Association between stress hyperglycemia ratio and in-hospital mortality in acute myocardial infarction: a dose-response meta-analysis.” BMC cardiovascular disorders (2026). PMID: 42092793 ↗
L2aCited in: Prognosis and Long-term Outcomes - [233]
Zhao Y, Jiang H, Zhao Y et al.. “Development and external validation of an admission-based model for 180-day mortality in diabetic acute myocardial infarction.” Frontiers in endocrinology (2026). PMID: 42466342 ↗
L3bCited in: Prognosis and Long-term Outcomes - [234]
Guimaraes AR, Williams SE, Macmillan MT et al.. “Machine Learning Multiorgan Analysis of Coronary CT Angiography Body Composition, Myocardial Infarction, and Mortality in the SCOT-HEART Trial.” Radiology (2026). PMID: 42377128 ↗
L3bCited in: Prognosis and Long-term Outcomes - [235]
Liu H, Hu S, Zhang Y et al.. “Development and Validation of an Interpretable Machine Learning Model for Predicting 1-Year Cardiac Death After Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction: A Multicenter Study.” Journal of the American Heart Association (2026). PMID: 42333686 ↗
L4Cited in: Prognosis and Long-term Outcomes - [236]
Gopal A, Kamrada C, Awad A et al.. “Association of Baseline SSRI use with post-STEMI outcomes in patients with depression.” International journal of cardiology (2026). PMID: 42203004 ↗
L3bCited in: Prognosis and Long-term Outcomes - [237]
van Steenwijk MPJ, Uitbeijerse LP, Pladet LCA et al.. “Association Between Preadmission β-Blocker Use and Venoarterial Extracorporeal Membrane Oxygenation Weaning Failure in Patients With Cardiogenic Shock.” Journal of the American Heart Association (2026). PMID: 42179258 ↗
L3bCited in: Prognosis and Long-term Outcomes - [238]
Hosseini F, Kang M, Segal T et al.. “Impact of malnutrition on outcomes among elderly ST-Elevation myocardial infarction patients receiving primary percutaneous coronary intervention.” American heart journal (2026). PMID: 42142827 ↗
L3bCited in: Prognosis and Long-term Outcomes - [239]
Lewin D, Nersesian G, Rojas SV et al.. “Impact of Partial- to Full-Support Escalation With Microaxial Flow Pumps Prior to Durable Left Ventricular Assist Device Implantation.” European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2026). PMID: 42087324 ↗
L4Cited in: Prognosis and Long-term Outcomes - [240]
Pesce F, Dini CS, Righini FM et al.. “Optimizing cardiogenic shock outcomes: A system-based network approach.” International journal of cardiology (2026). PMID: 42082006 ↗
L3bCited in: Prognosis and Long-term Outcomes - [241]
Tian J, Wang Z, Wang Y et al.. “Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease.” The New England journal of medicine (2026). PMID: 42456136 ↗
L1bCited in: Special Populations - [242]
Kharatha M, Rezaie S, Talebi SS et al.. “Effect of head and facial massage combined with aromatherapy on sleep quality and delirium in patients with acute myocardial infarction: A randomized controlled trial.” Complementary therapies in medicine (2026). PMID: 42336252 ↗
L1bCited in: Special Populations - [243]
Leissner P, Sundelin R, Rondung E et al.. “Randomized Controlled Trial of Internet-Delivered Cognitive Behavioral Therapy After Myocardial Infarction With Nonobstructive Coronary Arteries or Takotsubo Syndrome.” Journal of the American Heart Association (2026). PMID: 42294783 ↗
L1bCited in: Special Populations - [244]
Mirhosseini SA, Sadrzadeh SA, Semirani-Nezhad D et al.. “Baseline Ejection Fraction as a Modifier of Beta-Blocker Therapeutic Effects in Post-Acute Coronary Syndrome Patients With Non-Reduced Ejection Fraction: A Systematic Review and Meta-Analysis.” Cardiovascular therapeutics (2026). PMID: 42311050 ↗
L1aCited in: Special Populations - [245]
An X, Chen Y, Wang Y et al.. “Association Between Sleep Disorders and Adverse Cardiovascular Outcomes in Patients with Chronic Obstructive Pulmonary Disease: Insights from the UK Biobank.” International journal of chronic obstructive pulmonary disease (2026). PMID: 42306044 ↗
L2bCited in: Special Populations - [246]
Karalis DG, Richter B, Hessen S et al.. “Electronic Health Record Alerts to Improve Lipid Lowering After a Recent Myocardial Infarction.” Journal of the American Heart Association (2026). PMID: 42261954 ↗
L2bCited in: Special Populations - [247]
Wang C, Sakita FM, Prakash T et al.. “Long-Term Implementation and Effectiveness of a Quality Improvement Intervention for Myocardial Infarction in Tanzania.” Annals of global health (2026). PMID: 42404322 ↗
L3bCited in: Special Populations - [248]
Essa H, Balu A, Johnston B et al.. “Impact of new-onset atrial fibrillation on 12-month outcomes and mortality after esophagectomy.” Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (2026). PMID: 42328848 ↗
L3bCited in: Special Populations - [249]
Emori H, Shiono Y, Yamanobe H et al.. “Incidence of periprocedural myocardial injury and clinical outcomes after rotational atherectomy vs. intravascular lithotripsy.” International journal of cardiology (2026). PMID: 42314849 ↗
L3bCited in: Special Populations - [250]
Armentaro G, Crudo G, Menichelli D et al.. “Prognostic Role of Serum Albumin Levels in Elderly Patients With Non-Valvular Atrial Fibrillation.” European journal of clinical investigation (2026). PMID: 42299459 ↗
L3bCited in: Special Populations - [251]
Al-Naqdi MMA, Alkhammasi MLM, Al-Naqdi BMA. “Mortality Outcome Post-MI after PCI and CABG Interventions.” Global heart (2026). PMID: 42292644 ↗
L3bCited in: Special Populations - [252]
Filev R, Bogov B, Hadjieva R et al.. “Association of Acute-Phase IL-6 and SAA with Cardiovascular Events and Mortality Six Years After COVID-19 Infection: An Observational Cohort Study.” International journal of molecular sciences (2026). PMID: 42278254 ↗
L3bCited in: Special Populations